Methods for treating lysosomal acid lipase deficiency in patients

ABSTRACT

The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency. Methods of improving growth and river function, increasing LAL tissue concentration, and increasing LAL activity in a human patient suffering from LAL deficiency are also provided.

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No.61/403,011, filed Sep. 9, 2010, U.S. Provisional Application No.61/456,014, filed Oct. 29, 2010, U.S. Provisional Application No.61/432,372, filed Jan. 13, 2011, and PCT/US2011/033699, filed Apr. 23,2011. The entire teachings of the above applications are incorporatedherein by reference.

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

The content of the electronically submitted sequence listing in ASCIItext file (Name SequenceListing_ascii.txt; Size: 4,027 bytes; and Dateof Creation: Sep. 9, 2011) filed with the application is incorporatedherein by reference in its entirety.

BACKGROUND OF THE INVENTION

Lysosomal Acid Lipase (LAL) Deficiency is a rare lysosomal storagedisease (LSD) characterized by a failure to breakdown cholesteryl esters(CE) and triglycerides (TAG) in lysosomes due to a deficiency of theenzyme. LAL deficiency resembles other lysosomal storage disorders withthe accumulation of substrate in a number of tissues and cell types. InLAL deficiency substrate accumulation is most marked in cells of thereticuloendothelial system including Kupffer cells in the liver,histiocytes in the spleen and in the lamina propria of the smallintestine. Reticuloendothelial cells express the macrophagemannose/N-acetyl glucosamine receptor (also known as macrophage mannosereceptor, MMR, or CD206), which mediates binding, cell uptake andlysosomal internalization of proteins with GlcNAc or mannose terminatedN-glycans, and provides a pathway for the potential correction of theenzyme deficiency in these key cell types.

LAL Deficiency is a multi-system disease that most commonly manifestswith gastrointestinal, liver and cardiovascular complications and isassociated with significant morbidity and mortality. The clinicaleffects of LAL deficiency are due to a massive accumulation of lipidmaterial in the lysosomes in a number of tissues and a profounddisturbance in cholesterol and lipid homeostatic mechanisms, includingsubstantial increases in hepatic cholesterol synthesis. LAL deficiencypresents as at least two phenotypes: Wolman Disease (WD) and CholesterylEster Storage Disease (CESD).

Wolman Disease, named after the physician who first described it, is themost aggressive presentation of LAL deficiency. This phenotype ischaracterized by gastrointestinal and hepatic manifestations includinggrowth failure, malabsorption, steatorrhea, profound weight loss,lymphadenopathy, splenomegaly, and hepatomegaly. Wolman Disease israpidly progressive and invariably fatal usually within the first yearof life. Case report review indicates that survival beyond 12 months ofage is extremely rare for patients who present with growth failure dueto severe LAL deficiency in the first year of life. In this mostaggressive form, growth failure is the predominant clinical feature andis a key contributor to the early mortality. Hepatic involvement asevidenced by liver enlargement and elevation of transaminases is alsocommon in infants.

The diagnosis of Wolman Disease is established through both physicalfindings and laboratory analyses. Infants are typically hospitalizedwithin the first two months of life due to diarrhea, persistentvomiting, feeding difficulty, stunted growth, and failure to thrive.Physical findings include abdominal distention with hepatomegaly andsplenomegaly, and radiographic examination often reveals calcificationof the adrenal glands. Laboratory evaluations typically reveal elevatedlevels of serum transaminases and absent or markedly reduced endogenousLAL enzyme activity. Elevated blood levels of cholesterol andtriglycerides are seen in some patients.

Patients with LAL deficiency can also present later in life withpredominant liver and cardiovascular involvement, and this is oftencalled Cholesteryl Ester Storage Disease (CESD). In CESD, the liver isseverely affected with marked hepatomegaly, hepatocyte necrosis,elevation of transaminases, cirrhosis, and liver fibrosis. Due toincreased levels of CE and TAG, the cardiovascular involvement can becharacterized by hyperlipidemia. An accumulation of fatty deposits onthe artery walls (atherosclerosis) has been reported in some subjectssuffering from CESD. The deposits narrow the arterial lumen and can leadto vessel occlusion increasing the risk of significant cardiovascularevents including myocardial infarction and strokes. However, not allsubjects suffering from LAL deficiency develop atherosclerosis. Forexample, Wolman Disease patients are overwhelmed with other symptomsassociated with the disease, including enlarged liver and spleen,lymphadenopathy, and the malabsorption by the small intestine, but WD isnot generally characterized by atherosclerosis (The Metabolic andMolecular Bases of Inherited Disease (Scriver, C. R., Beaudet, A. L.,Sly, W. S. and Valle D., eds) 7th ed., Volume 2 p. 2570 McGraw-Hill,1995). Likewise, not all CESD patients exhibit atherosclerosis See, DiBisceglie et al., Hepatology 11: 764-772 (1990), Ameis et al., J. LipidRes. 36: 241-250 (1995). The presentation of CESD is highly variablewith some patients going undiagnosed until complications manifest inlate adulthood, while others can have liver dysfunction presenting inearly childhood. CESD is associated with shortened lifespan andsignificant ill health. The life expectancy of those with CESD dependson the severity of the associated complications.

Current treatment options for Wolman Disease are very limited.Antibiotics are administered to infants with pyrexia and/or evidence ofinfection. Steroid replacement therapy for adrenal insufficiency andspecialized nutritional support may be prescribed, and while there is noevidence that these interventions prevent death, it is also unclear atpresent if they have an impact on short term survival. In a series offour patients with LAL deficiency treated with bone marrowtransplantation, all four patients died due to complications of theprocedure within months of transplantation. Although some success hasbeen described in subsequent case reports, the mortality rate remainshigh and many patients are not transplanted as they are too ill tosurvive the pre-transplant conditioning regime. The very small number ofreported long-term survivors does indicate that correction of enzymedeficiency in hemopoietic cells alone is sufficient to substantiallyimprove the clinical status in this disease. Typically clinical supportis provided through dietary restrictions in an attempt to restrict thebuild-up of nontransportable and noncatabolizable lipids associated withthe acute manifestations of the disease leading to death.

Current treatment options for the CESD phenotype are focused atsymptomatic treatment via control of lipid accumulation through dietthat excludes foods rich in cholesterol and triglycerides andsuppression of cholesterol synthesis and apolipoprotein B productionthrough administration of cholesterol lowering drugs (e.g., statins andcholestyramine). Although some clinical improvement may be seen, theunderlying disease manifestations persist and disease progression stilloccurs.

It has been suggested that enzyme replacement therapy with recombinantLAL may be a viable treatment option for lysosomal acid lipasedeficiency and related conditions (see, Meyers et al. (1985) NutritionRes. 5(4):423-442; WO9811206; and Besley (1984) Clinical Genetics26:195-203). Some studies using a mouse model of LAL deficiency havedemonstrated correction of some abnormalities of LAL deficient(LAL^(−/−)) mice through infusion of high doses (more than 1 milligramper kilogram of body weight) of recombinant human LAL once every 3 days(see, for example, Grabowski US 2007/0264249). These earlier studies tocorrect the defects within LAL deficient mice suggested that relativelyhigh amounts and frequent dosages of recombinant LAL protein wererequired in order to correct the underlying phenotypes. It is alsoimportant to note that, unlike the LAL^(−/−) rat model describedinitially by Yoshida and Kuriyama (1990) Laboratory Animal Science, vol40, p 486-489, the LAL^(−/−) mice model used in the above study does notclosely resemble human WD in that the LAL deficient mice do not exhibitgrowth defects that are seen in human patients.

To date, no exogenous LAL has been administered to humans and there isno effective therapy available for treating LAL deficiencies includingWD, CESD, and others. Therefore, there is a dire need for therapies witha minimized frequency of administration in order to improve the qualityof life for patients. Further, therapeutically effective doses thatrestore growth, normalize liver function, increase LAL tissueconcentrations, and increase LAL activity in human patients aredesirable.

SUMMARY OF THE INVENTION

The present invention is based on the first human clinical cases inwhich patients were successfully dosed with exogenous LAL. An infantsuffering from an otherwise fatal form of LAL Deficiency (WolmanDisease, or early onset LAL Deficiency) was effectively treated byadministering exogenous LAL, and safety assessment of LAL enzymereplacement therapy was assessed on a group of human patients sufferingfrom late onset LAL deficiency. The infant with early onset LALdeficiency was administered weekly low doses without eliciting anyadverse events or reactions. Dramatic improvements in vital signs andclinical/laboratory measurements for efficacy were observed as early asone to two weeks following the initial administration. After over 4months of weekly dosing, the treated infant had restored normal growthand exhibited significant improvements in all symptoms related to LALdeficiency including malabsorption, hepatomegaly, and liver function.Late onset adult patients have also been dosed weekly with low amountsof exogenous LAL, with no signs of adverse events. Therefore, theclinical data collected to date show that enzyme replacement therapyusing the exogenous LAL of the present invention provides safe andeffective treatment for LAL deficiency.

Accordingly, the present invention provides methods of treating diseasesor conditions associated with LAL deficiency in human patients byadministering an effective amount of exogenous lysosomal acid lipase(LAL). The exogenous LAL can be a recombinant human LAL that has anN-linked glycan structure comprising at least one mannose and/ormannose-6-phosphate. The exogenous LAL is effectively internalized intothe lysosome of, e.g., lymphocytes, macrophages, and/or fibroblasts.

In some embodiments, the human patient suffering from LAL deficiency isdiagnosed with Wolman disease (WD). In one embodiment, theadministration is sufficient to increase growth of a WD patient. In oneembodiment, the administration is sufficient to restore normal growth ofthe WD patient. In other embodiments, the human patient suffering fromLAL deficiency is diagnosed with cholesteryl ester storage disease(CESD). The treatment methods according to the present invention can beprovided to human patients of any age.

Also provided herein are methods for treating a human patient sufferingfrom LAL deficiency by administering recombinant human LAL to thepatient in an effective amount to improve liver function. In someembodiments, the administration is sufficient to normalize liver tests.In one embodiment, the administration is sufficient to decrease serumlevels of liver transaminases. For example, the liver transaminases caninclude serum aspartate transaminase (AST) and/or alanine transaminase(ALT). In one embodiment, the administration is sufficient to minimizehepatomegaly. In one embodiment, the administration is sufficient todecrease liver size of the patient. In one embodiment, theadministration is sufficient to decrease serum ferritin levels.

In one embodiment, the administration is sufficient to decrease serumlipid levels, including, for example, cholesteryl ester (CE) and/ortriglycerides (TG) levels.

Also provided is a method of increasing LAL activity in a human patientwith a LAL deficiency. Such method comprises administering recombinanthuman LAL to the patient so that the administration results in increasedLAL activity, as can be measured, for example, in lymphocytes and/orfibroblasts.

In one embodiment, a method of treating a condition associated with LALdeficiency in a human patient by administering an effective amount ofexogenous LAL protein to the patient one time every 5 days to one timeevery 30 days is described.

In some embodiments, the human patient suffering from LAL deficiency isdosed about 0.1 mg to about 50 mg of exogenous LAL per kilogram of bodyweight. In one embodiment, the human patient is dosed about 0.1 mg toabout 10 mg of exogenous LAL per kilogram of body weight. In oneembodiment, the human patient is dosed about 0.1 mg to about 5 mg ofexogenous LAL per kilogram of body weight.

In one embodiment, an infusion rate is between about 0.1 mg/kg/hr andabout 4 mg/kg/hr.

In some embodiments, the human patient is treated with a secondtherapeutic. The second therapeutic can include, for example, acholesterol-reducing drug (e.g., statin or ezetimibe), an antihistamine(e.g., diphenhydramine), or an immunosuppressant.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A depicts levels of serum aspartate transaminase (AST) of aninfantile male Wolman disease (i.e., early onset LAL deficiency) patientwho received weekly dosing of exogenous LAL (SBC-102) (dose: 0.2 mg/kg(initial infusion; week 0); 0.3 mg/kg (week 1); 0.5 mg/kg (week 2); and1.0 mg/kg (weeks 3-8)). FIG. 1B depicts levels of serum alaninetransaminase (ALT) of the same patient. The patient was 4 months and 1week old at the initial infusion.

FIG. 2 depicts levels of serum ferritin of the Wolman disease patientwho received weekly dosing of exogenous LAL (SBC-102) (dose: 0.2 mg/kg(initial infusion; week 0); 0.3 mg/kg (week 1); 0.5 mg/kg (week 2); and1.0 mg/kg (weeks 3-8)). The patient was 4 months and 1 week old at theinitial infusion. The serum ferritin levels are shown from the week 1following the initial dosing at week 0.

FIG. 3 depicts growth velocity of the Wolman disease patient whoreceived weekly dosing of exogenous LAL (SBC-102) (dose: 0.2 mg/kg(initial infusion; week 0); 0.3 mg/kg (week 1); 0.5 mg/kg (week 2); and1.0 mg/kg (weeks 3-8)).

FIG. 4 depicts a growth curve of the Wolman disease patient (kg,weight-for-age percentiles for boys).

FIG. 5 depicts serum AST levels of a 41-year old white male CESD patientwho received weekly doses of 0.35 mg/kg of exogenous LAL.

FIG. 6 depicts serum ALT levels of a 41-year old white male CESD patientwho received weekly doses of 0.35 mg/kg of exogenous LAL.

FIG. 7 depicts serum albumin levels of a 41-year old white male CESDpatient who received weekly doses of 0.35 mg/kg of exogenous LAL.

FIG. 8 depicts serum ferritin levels of a 41-year old white male CESDpatient who received weekly doses of 0.35 mg/kg of exogenous LAL.

FIG. 9 illustrates the rate of weight gain in four age-matched, malerats each assigned to one of the following four exogenous LAL dosageregimes: 1 mg per kilogram once a week, 5 mg per kilogram once a week, 5mg per kilogram once every 2 weeks, or placebo. Numbers inside thecolumns represent days post birth.

FIG. 10 depicts the results of pathological and histopathologicalexamination of a wild-type control, an LAL deficient rat treated withexogenous LAL, and an LAL deficient placebo-treated rat. Gross pathologydemonstrates a normalization of color and size of the liver in ratstreated with exogenous LAL. Histopathology of liver tissue from ratstreated with exogenous LAL shows essentially normal liver histology inmarked contrast to the substantial accumulation of foamy macrophages inthe placebo-treated animals.

FIG. 11 depicts the co-localization of recombinant human LAL (SBC-102)and lysosomal marker in the lysosomes of cells examined by confocalfluorescence microscopy using a sequential scanning mode.

FIG. 12 depicts the binding specificity of recombinant human LAL(SBC-102) to the GlcNAc/mannose receptor assessed by competitive bindingassays using the macrophage cell line, NR8383.

FIG. 13 depicts the activity of recombinant human LAL in cells in normaland LAL-deficient cells in vitro.

FIG. 14 illustrates the effect of recombinant human LAL (SBC-102)treatment on internal organs mass of LAL deficient rats. Organ size isrepresented as percent of body weight determined at 8 weeks of age, inLAL^(−/−) rats and LAL^(+/+) rats after weekly administration of vehicleor SBC-102 at 5 mg/kg for 4 weeks.

FIG. 15 illustrates body weight in wild type and LAL-deficient ratsafter weekly dose of vehicle or SBC-102 at 5 mg·kg⁻¹ for 4 weeks. Doseadministration is highlighted on X-axis by diamonds starting at 4 week.

FIG. 16 depicts levels of liver cholesterol, cholesteryl ester andtriglyceride determined at 8 weeks of age in WT and LAL deficient ratsafter weekly dose of vehicle or SBC-102 at 5 mg·kg⁻¹ for 4 weeks.

FIG. 17 depicts percent increase of body weight in LAL-deficient rats.

FIG. 18 depicts liver weight, as a percent of body weight, inLAL-deficient rats after administration of SBC-102 for 4 weeks.

FIG. 19 illustrates levels of tissue cholesteryl ester in LAL-deficientrats after administration of SBC-102 for 4 weeks.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides methods for treating a human sufferingfrom a disease or condition which is responsive to the administration ofexogenous lysosomal acid lipase.

Definitions

For convenience, certain terms employed in the specification, examples,and appended claims are set forth herein to illustrate and define themeaning and scope of the various terms used to describe the presentinvention.

“LAL” as used herein refers to “lysosomal acid lipase,” and the twoterms are used interchangeably throughout the specification. The LAL canbe a human protein, i.e., human lysosomal acid lipase. The term“SBC-102,” as used herein, refers to a recombinant human lysosomal acidlipase. LAL is also referred to in the literature as acid cholesterylester hydrolase, cholesteryl esterase, Lipase A, LIPA, and sterolesterase.

LAL catalyzes the hydrolysis of cholesterol esters and triglycerides tofree cholesterol, glycerol, and tree fatty acids. Thus, “LAL activity”can be measured, for example, by the cleavage of the fluorogenicsubstrate, 4-methylumbelliferyl oleate (4MUO). Cleavage of 4MUO can bedetected, for example, by excitation at about 360 nm and emission at 460nm of the released flurophore, 4-methylumbelliferone (4MU). Results canbe reported in relative fluorescence units (RFU). For example, theamount of substrate cleaved in a 30 minute endpoint assay can bequantified relative to a 4MU standard curve, and one unit (U) ofactivity can be defined as the amount of enzyme required to cleave 1micromole of 4MUO per minute at 37° C. Accordingly, functional fragmentsor variants of LAL include fragments or variants that have LAL activity,e.g., the ability to hydrolyze cholesterol esters and/or triglycerides.

As used herein “exogenous LAL” refers to LAL that is not naturallyproduced by a patient. For example, exogenous LAL includes recombinantLAL protein that is administered to a patient, LAL protein that isisolated from a person or animal and administered to a patient, and LALprotein that is produced (i.e., expressed) in a patient as a result ofadministration of LAL-encoding RNA and/or DNA or another treatment thatincreases expression of endogenous LAL protein.

“Intravenous injection,” often medically referred to as IV push or bolusinjection, refers to a route of administration in which a syringe isconnected to the IV access device and the medication is injecteddirectly, typically rapidly and occasionally up to a period of 15minutes if it might cause irritation of the vein or a too-rapid effect.Once a medicine has been injected into the fluid stream of the IVtubing, there must be some means of ensuring that it gets from thetubing to the patient. Usually this is accomplished by allowing thefluid stream to flow normally and thereby carry the medicine into thebloodstream. However, in some cases a second fluid injection, sometimescalled a “flush,” is used following the first injection to facilitatethe entering of the medicine into the bloodstream.

“Intravenous infusion” refers to a route of administration in whichmedication is delivered over an extended period of time. For example,the medication can be delivered to a patient over a period of timebetween 1 and 8 hours. The medication can also be delivered to a patientover a period of about 1, about 2, about 3, about 4, about 5, about 6,about 7, or about 8 hours. To accomplish an intravenous infusion, an IVgravity drip or an IV pump can be used. IV infusion is typically usedwhen a patient requires medications only at certain times and does notrequire additional intravenous fluids (e.g., water solutions which cancontain sodium, chloride, glucose, or any combination thereof) such asthose that restore electrolytes, blood sugar, and water loss.

The term “avian” as used herein refers to any species, subspecies orrace of organism of the taxonomic class ayes, such as, but not limitedto chicken, turkey, duck, goose, quail, pheasants, parrots, finches,hawks, crows, and ratites including ostrich, emu and cassowary. The termincludes the various known strains of Gallus gallus, or chickens (forexample, White Leghorn, Brown Leghorn, Barred-Rock, Sussex, NewHampshire, Rhode Island, Australorp, Minorca, Amrox, California Gray),as well as strains of turkeys, pheasants, quails, duck, ostriches, andother poultry commonly bred in commercial quantities. It also includesan individual avian organism in all stages of development, includingembryonic and fetal stages.

The term “poultry derived” or “avian derived” refers to a composition orsubstance produced by or obtained from poultry. “Poultry” refers toavians that can be kept as livestock, including but not limited to,chickens, duck, turkey, quail and ratites. For example, “poultryderived” may refer to chicken derived, turkey derived and/or quailderived.

The term “patient” as used herein refers to any person receiving or whohas received or is to receive medical care or treatment, e.g, asdirected by a medical care provider.

“Therapeutically effective dose” as used herein refers to the dose(e.g., amount and/or interval) of drug required to produce an intendedtherapeutic response. A therapeutically effective dose refers to a dosethat, as compared to a corresponding subject who has not received such adose, results in improved treatment, healing, prevention, oramelioration of a disease, disorder, or side effect, or a decrease inthe rate of the occurrence or advancement of a disease or disorder. Theterm also includes within its scope, doses effective to enhancephysiological functions.

The terms “treat,” “treating,” and “treatment” refer to methods ofalleviating, abating, or ameliorating a disease or symptom, preventingan additional symptom, ameliorating or preventing an underlying cause ofa symptom, inhibiting a disease or condition, arresting the developmentof a disease or condition, relieving a disease or condition, causingregression of a disease or condition, relieving a condition caused bythe disease or condition, or stopping a symptom of the disease orcondition either prophylactically and/or after the symptom has occurred.

As used herein with reference to a particular dose, “kg⁻¹”, “per kg”,“/kg,” and “per kilogram” represent “per kilogram of body weight” of themammal, and thus the terms can be used interchangeably.

As used herein, the term “polypeptide” is intended to encompass asingular “polypeptide” as well as plural “polypeptides,” and refers to amolecule composed of monomers (amino acids) linearly linked by amidebonds (also known as peptide bonds). The term “polypeptide” refers toany chain or chains of two or more amino acids, and does not refer to aspecific length of the product. Thus, peptides, dipeptides, tripeptides,oligopeptides, “proteins,” “amino acid chains,” or any other term usedto refer to a chain or chains of two or more amino acids, are includedwithin the definition of “polypeptide,” and the teen “polypeptide” maybe used instead of, or interchangeably with any of these terms. The term“polypeptide” is also intended to refer to the products ofpost-expression modifications of the polypeptide, including withoutlimitation glycosylation, acetylation, phosphorylation, amidation,derivatization by known protecting/blocking groups, proteolyticcleavage, or modification by non-naturally occurring amino acids. Apolypeptide may be derived from a natural biological source or producedby recombinant technology, but is not necessarily translated from adesignated nucleic acid sequence. It may be generated in any manner,including by chemical synthesis.

As used herein, the percent homology between two amino acid sequences ortwo nucleotide sequences is equivalent to the percent identity betweenthe two sequences. The percent identity between the two sequences is afunction of the number of identical positions shared by the sequences(i.e., % homology=# of identical positions/total # of positions ×100),taking into account the number of gaps, and the length of each gap,which need to be introduced for optimal alignment of the two sequences.The comparison of sequences and determination of percent identitybetween two sequences can be accomplished using a mathematicalalgorithm, as described in the non-limiting examples below.

The percent identity between two amino acid sequences can be determinedusing the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci.,4:11-17 (1988)), which has been incorporated into the ALIGN program(version 2.0), using a PAM120 weight residue table, a gap length penaltyof 12 and a gap penalty of 4. In addition, the percent identity betweentwo amino acid sequences can be determined using the Needleman andWunsch (J. Mol, Biol. 48:444-453 (1970)) algorithm which has beenincorporated into the GAP program in the GCG software package (availableat http://www.gcg.com), using either a Blossom 62 matrix or a PAM250matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a lengthweight of 1, 2, 3, 4, 5, or 6.

By an “isolated” polypeptide or a fragment, variant, or derivativethereof is intended a polypeptide that is not in its natural milieu. Noparticular level of purification is required. For example, an isolatedpolypeptide can be removed from its native or natural environment.Recombinantly produced polypeptides and proteins expressed in host cellsare considered isolated as disclosed herein, as are native orrecombinant polypeptides which have been separated, fractionated, orpartially or substantially purified by any suitable technique.

Other polypeptides disclosed herein are fragments, derivatives, analogs,or variants of the foregoing polypeptides, and any combination thereof.The terms “fragment,” “variant,” “derivative” and “analog” whenreferring to any of the polypeptides disclosed herein include anypolypeptides which retain at least some of the activity of thecorresponding native polypeptide (e.g., LAL polypeptide fragments,variants, derivatives, and analogs that retain the ability to hydrolyzecholesterol esters and/or triglycerides). Fragments of polypeptidesinclude, for example, proteolytic fragments, as well as deletionfragments. Variants of a polypeptide include fragments as describedabove, and also polypeptides with altered amino acid sequences due toamino acid substitutions, deletions, or insertions. Variants can occurnaturally or be non-naturally occurring. Non-naturally occurringvariants can be produced using art-known mutagenesis techniques. Variantpolypeptides can comprise conservative or non-conservative amino acidsubstitutions, deletions, or additions. Derivatives are polypeptideswhich have been altered so as to exhibit additional features not foundon the native polypeptide. Examples include fusion proteins. Variantpolypeptides can also be referred to herein as “polypeptide analogs.” Asused herein, a “derivative” of a subject polypeptide can contain one ormore residues chemically derivatized by reaction of a functional sidegroup. Also included as “derivatives” are those peptides which containone or more naturally occurring amino acid derivatives of the twentystandard amino acids. For example, 4-hydroxyproline can be substitutedfor proline; 5-hydroxylysine can be substituted for lysine;3-methylhistidine can be substituted for histidine; homoserine can besubstituted for serine; and/or ornithine can be substituted for lysine.

The terra “polynucleotide” is intended to encompass a singular nucleicacid as well as plural nucleic acids, and refers to an isolated nucleicacid molecule or construct, e.g., messenger RNA (mRNA) or plasmid DNA(pDNA). A polynucleotide may comprise a conventional phosphodiester bondor a non-conventional bond (e.g., an amide bond, such as found inpeptide nucleic acids (PNA)). The term “nucleic acid” refers to any oneor more nucleic acid segments, e.g., DNA or RNA fragments, present in apolynucleotide. By “isolated” nucleic acid or polynucleotide is intendeda nucleic acid molecule, DNA or RNA, which has been removed from itsnative environment. For example, a recombinant polynucleotide encodingLAL contained in a vector is considered isolated for the purposes of thepresent invention. Further examples of an isolated polynucleotideinclude recombinant polynucleotides maintained in heterologous hostcells or purified (partially or substantially) polynucleotides insolution, Isolated RNA molecules include in vivo or in vitro RNAtranscripts of polynucleotides of the present invention. Isolatedpolynucleotides or nucleic acids according to the present inventionfurther include such molecules produced synthetically. In addition, apolynucleotide or a nucleic acid can be or can include a regulatoryelement such as a promoter, ribosome binding site, or a transcriptionterminator.

As used herein, a “coding region” is a portion of nucleic acid whichconsists of codons translated into amino acids. Although a “stop codon”(TAG, TGA, or TAA) is not translated into an amino acid, it may beconsidered to be part of a coding region, but any flanking sequences,for example promoters, ribosome binding sites, transcriptionalterminators, introns, and the like, are not part of a coding region. Twoor more coding regions of the present invention can be present in asingle polynucleotide construct, e.g., on a single vector, or inseparate polynucleotide constructs, e.g., on separate (different)vectors. Furthermore, any vector can contain a single coding region, orcan comprise two or more coding regions. In addition, a vector,polynucleotide, or nucleic acid of the invention can encode heterologouscoding regions, either fused or unfused to a nucleic acid encoding a LALpolypeptide or fragment, variant, or derivative thereof. Heterologouscoding regions include without limitation specialized elements ormotifs, such as a secretory signal peptide or a heterologous functionaldomain.

A variety of transcription control regions are known to those skilled inthe art. These include, without limitation, transcription controlregions which function in vertebrate cells, such as, but not limited to,promoter and enhancer segments from cytomegaloviruses (the immediateearly promoter, in conjunction with intron-A), simian virus 40 (theearly promoter), and retroviruses (such as Rous sarcoma virus). Othertranscription control regions include those derived from vertebrategenes such as actin, heat shock protein, bovine growth hormone andrabbit β-globin, as well as other sequences capable of controlling geneexpression in eukaryotic cells. Additional suitable transcriptioncontrol regions include tissue-specific promoters and enhancers as wellas lymphokine-inducible promoters (e.g., promoters inducible byinterferons or interleukins).

Similarly, a variety of translation control elements are known to thoseof ordinary skill in the art. These include, but are not limited toribosome binding sites, translation initiation and termination codons,and elements derived from picornaviruses (particularly an internalribosome entry site, or IRES, also referred to as a CITE sequence).

In other embodiments, a polynucleotide of the present invention is RNA,for example, in the form of messenger RNA (mRNA).

Polynucleotide and nucleic acid coding regions of the present inventionmay be associated with additional coding regions which encode secretoryor signal peptides, which direct the secretion of a polypeptide encodedby a polynucleotide of the present invention. According to the signalhypothesis, proteins secreted by mammalian cells have a signal peptideor secretory leader sequence which is cleaved from the mature proteinonce export of the growing protein chain across the rough endoplasmicreticulum has been initiated. Those of ordinary skill in the art areaware that polypeptides secreted by vertebrate cells generally have asignal peptide fused to the N-terminus of the polypeptide, which iscleaved from the complete or “full length” polypeptide to produce asecreted or “mature” form of the polypeptide. In certain embodiments,the native signal peptide, e.g., the MKMRFLGLVVCLVLWTLHSEG (SEQ ID NO:2)signal peptide of human LAL is used, or a functional derivative of thatsequence that retains the ability to direct the secretion of thepolypeptide that is operably associated with it. Alternatively, aheterologous signal peptide (e.g., a heterologous mammalian or aviansignal peptide), or a functional derivative thereof, may be used. Forexample, the wild-type leader sequence may be substituted with theleader sequence of human tissue plasminogen activator (TPA) or mouseβ-glucuronidase.

“Vector” means a polynucleotide comprised of single strand, doublestrand, circular, or supercoiled DNA or RNA. A typical vector can becomprised of the following elements operatively linked at appropriatedistances for allowing functional gene expression: replication origin,promoter, enhancer, 5′ mRNA leader sequence, ribosomal binding site,nucleic acid cassette, termination and polyadenylation sites, andselectable marker sequences. One or more of these elements can beomitted in specific applications. The nucleic acid cassette can includea restriction site for insertion of the nucleic acid sequence to beexpressed. In a functional vector the nucleic acid cassette contains thenucleic acid sequence to be expressed including translation initiationand termination sites. An intron optionally can be included in theconstruct, for example, 5″ to the coding sequence. A vector isconstructed so that the particular coding sequence is located in thevector with the appropriate regulatory sequences, the positioning andorientation of the coding sequence with respect to the control sequencesbeing such that the coding sequence is transcribed under the “control”of the control or regulatory sequences. Modification of the sequencesencoding the particular protein of interest can be desirable to achievethis end. For example, in some cases it can be necessary to modify thesequence so that it can be attached to the control sequences with theappropriate orientation, or to maintain the reading frame. The controlsequences and other regulatory sequences can be ligated to the codingsequence prior to insertion into a vector. Alternatively, the codingsequence can be cloned directly into an expression vector which alreadycontains the control sequences and an appropriate restriction site whichis in reading frame with and under regulatory control of the controlsequences.

The term “expression” as used herein refers to a process by which a geneproduces a biochemical, for example, a polypeptide. The process includesany manifestation of the functional presence of the gene within the cellincluding, without limitation, gene knockdown as well as both transientexpression and stable expression. It includes without limitationtranscription of the gene into messenger RNA (mRNA), and the translationof such mRNA into polypeptide(s). Expression of a gene produces a “geneproduct.” As used herein, a gene product can be either a nucleic acid,e.g., a messenger RNA produced by transcription of a gene, or apolypeptide which is translated from a transcript. Gene productsdescribed herein further include nucleic acids with post transcriptionalmodifications, e.g., polyadenylation, or polypeptides with posttranslational modifications, e.g., methylation, glycosylation, theaddition of lipids, association with other protein subunits, proteolyticcleavage, and the like.

As used herein, “host cells” refers to cells that harbor vectorsconstructed using recombinant DNA techniques and encoding at least oneheterologous gene.

As used herein the terms “N-glycan,” “oligosaccharide,” “oligosaccharidestructure,” “glycosylation pattern,” “glycosylation profile,” and“glycosylation structure” have essentially the same meaning and eachrefer to one or more structures which are formed from sugar residues andare attached to glycosylated proteins.

As used herein, the term “pharmaceutical composition” refers to amixture of a compound described herein with other chemical components,such as carriers, stabilizers, diluents, dispersing agents, suspendingagents, thickening agents, and/or excipients.

Patients with Insufficient LAL Activity

Without wishing to limit the invention to the treatment of anyparticular condition or group of conditions, the invention includes thetreatment of lysosomal acid lipase (LAL) deficiencies in patients. Asused herein, a patient with a LAL deficiency is any patient that hasinsufficient LAL activity. The insufficient LAL activity in the patientcan, for example, be the result of low RNA levels, low protein levels,or low protein activity. The insufficient LAL activity can result from amutation in the LAL coding sequence, a LAL regulatory sequence, or inanother gene (e.g., a gene that regulates LAL). Insufficient LALactivity can also be the result of environmental factors.

The present invention can be used to treat a wide array of conditions ina subject or patient. Therefore, any condition that can be beneficiallytreated by exogenous LAL in accordance with the invention is includedwithin the scope of the invention.

One embodiment of the invention focuses on the treatment of lysosomalstorages diseases (LSDs) that result from a deficiency in lysosomal acidlipase, specifically Wolman Disease (WD) and Cholesteryl Ester StorageDisease (CESD). Without wishing to limit the invention to any particulartheory or mechanism of operation, both WD and CESD can be due tomutations at the LAL locus and result in a massive accumulation of lipidmaterial in the lysosomes in a number of tissues and a profounddisturbance in cholesterol and lipid homeostatic mechanisms which can betreated by administration of exogenous LAL in accordance with themethods of the invention. Thus, in one embodiment, the LAL deficiencytreated in accordance with the invention is WD. In another embodiment,the LAL deficiency treated in accordance with the invention is CESD. Insome embodiments, a diagnosis of WD or CESD is based on genetic analysis(e.g. identification of a functional mutation in a LAL-encodingsequence). In other embodiments, a diagnosis of WD or CESD is based onclinical findings (e.g., physical examination and/or laboratory tests).

In some embodiments, exogenous LAL can be used to treat complications ina variety of conditions such as Non-Alcoholic Fatty Liver Disease(NAFLD) and Non-Alcoholic Steatohepatitis (NASH). NAFLD refers to adisease of the liver which has similar histopathology to liver diseasethat is due to excessive intake of alcohol. It is characterized bymacrovesicularsteatosis which causes enlargement of the liver. NAFLD canprogress into NASH which refers to liver disease that is similar toNAFLD with the addition of inflammation and damage to the liver whichcan lead to fibrosis and cirrhosis.

In some embodiments, exogenous LAL can be used to treat conditionsincluding pancreatitis, for example, chronic pancreatitis and/or acutepancreatitis as well as alcohol induced pancreatic injury such asalcohol induced pancreatitis.

Exogenous LAL produced by any useful method can be used to treatdiseases due to alcohol induced cell injury including, but not limitedto, those alcohol induced cell injuries that result in accumulation oflipid esters in body tissue such as, but not limited to, liver, spleen,gut, and cardiovascular tissue. According to the invention,malabsorption can also be treated by administering exogenous LAL.Exogenous LAL is also useful for the treatment of patients with Tangierdisease and familial hypoalphalipoproteinemia. Tangier disease/familialhypoalphalipo-proteinemia is associated with the accumulation ofcholesterol esters in macrophages accompanied by hepatosplenomegalyand/or lymphadenopathy along with low HDL levels which can be treated bythe administration of exogenous LAL. For example, without wishing tolimit the invention to any particular theory or mechanism of operation,impaired LAL activity can decrease ABCA1 expression and conversely anincreased LAL activity obtained by the administration of exogenous LALto a patient with Tangier disease/familial hypoalphalipoproteinemia willincrease ABCA1 expression to overcome the effects of an ABCA1 gene witha reduced functional activity as a result of polymorphism.

In some embodiments, the level of LAL activity in a patient prior totreatment is about 1%, about 2%, about 3%, about 5%, about 10%, about15%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%,or about 80% of normal levels of LAL activity. In one embodiment, thelevel of LAL activity in a patient prior to treatment is about 50% orless of normal levels of LAL activity. In one embodiment, the level ofLAL activity in a patient prior to treatment is about 40% or less ofnormal levels of LAL activity. In some embodiments, the level of LALactivity in a patient prior to treatment is about 30% or less of normallevels of LAL activity. In some embodiments, the level of LAL activityin a patient prior to treatment is about 30% or less of normal levels ofLAL activity. In some embodiments, the level of LAL activity in apatient prior to treatment is about 20% or less of normal levels of LALactivity. In some embodiments, the level of LAL activity in a patientprior to treatment is about 10% or less of normal levels of LALactivity. In some embodiments, the level of LAL activity in a patientprior to treatment is about 5% or less of normal levels of LAL activity.In some embodiments, a patient shows no measurable LAL activity prior totreatment.

In some embodiments, the level of LAL activity is measured in culturedfibroblast obtained from a human patient suffering from LAL deficiency.In some embodiments, the level of LAL activity is measured inlymphocytes (e.g., leukocytes) of a human patient suffering from LALdeficiency. The lymphocytes include, but are not limited to, peripheralblood mononuclear cells (PMBC). Methods for the measurement aredescribed, for example, in Burton et al., (1980) Clinica Chimica Acta101: 25-32, and in Anderson et al., (1999) Mol. Genet. & Metab., 66:333-345, both of which are incorporated herein in their entireties. LALdeficient patients who are to be treated with exogenous LAL can exhibitfibroblast LAL enzymatic activity that is less than about 30, about 20,about 10, about 5, about 4, about 3, about 2 or about 1 pmol/mg/min asmeasured using triolein as a substrate. LAL deficient patients who areto be treated with exogenous LAL can exhibit leukocyte LAL enzymaticactivity that is less than about 30, about 20, about 10, about 5, about4, about 3, about 2 or about 1 pmol/mg/min as measured by triolein as asubstrate. LAL deficient patients who are to be treated with exogenousLAL can exhibit fibroblast LAL enzymatic activity that is less thanabout 30, about 20, about 10, about 5, about 4, about 3, about 2 orabout 1 pmol/mg/min as measured using cholesteryl oleate as a substrate.LAL deficient patients who are to be treated with exogenous LAL canexhibit leukocyte LAL enzymatic activity that is less than about 30,about 20, about 10, about 5, about 4, about 3, about 2 or about 1pmol/mg/min as measured using cholesteryl oleate as a substrate.

Administration of Exogenous LAL

The invention provides methods of treating human patients with exogenousLAL comprising administering exogenous LAL to the patient, wherein theadministration is sufficient to restore growth, to improve liverfunction, to reduce liver damage, to increase tissue levels of LAL,and/or increase LAL activity in the patient. The invention providesuseful and previously uncharacterized frequencies of administration(i.e., dosing schedules) of exogenous LAL to treat conditions stemmingfrom LAL deficiency, including WD and CESD, as well as previouslyuncharacterized dosing amounts for treatment of these conditions.

The invention provides for a therapeutically effective dose of exogenousLAL to be administered to a patient between one time every 5 days andone time every 30 days for a period of time determined by a practitionerof skill in the art of medical sciences. In one embodiment, the periodof time will be the remainder of the patient's life span. In oneembodiment, the dosing frequency is between one time every 5 days andone time every 25 days. In one embodiment, the dosing frequency isbetween one time every 5 days and one time every 21 days. In anotherembodiment, the dosing frequency is between one time every 7 days andone time every 14 days. The exogenous LAL can be administered one timeevery 5 days, one time every 6 days, one time every 7 days, one timeevery 8 days, one time every 9 days, one time every 10 days, one timeevery 11 days, one time every 12 days, one time every 13 days, or onetime every 14 days. In some embodiments, the exogenous LAL isadministered about weekly. In other embodiments, the exogenous LAL isadministered about bi-weekly. In one embodiment, the dosing frequency isabout one time every 30 days.

For the treatment of a condition, generally, the amount of exogenous LALadministered can vary depending on known factors such as age, health,and weight of the recipient, type of concurrent treatment, frequency oftreatment, and the like. Usually a dosage of active ingredient can beabout 0.01 to about 50 mg per kilogram of body weight. In oneembodiment, dosage of exogenous LAL in accordance with the invention isabout 0.1 to 0.5 mg per kilogram of body weight. In one embodiment, thedose is about 0.1 mg to about 5.0 mg per kilogram. In one embodiment,the dose is about 0.1 mg to about 5.0 mg per kilogram. In one embodimentthe dose is about 0.1, about 0.2, about 0.25, about 0.30, about 0.35,about 0.40, about 0.45, about 0.50 mg per kilogram. In one embodiment,the dose is about 1 mg to about 5 mg per kilogram. In one embodiment,the dose is about 1 mg per kilogram. In one embodiment, the dose isabout 3 mg per kilogram. For example, 0.1 mg per kilogram of bodyweight, 0.2 mg per kilogram of body weight, 0.3 mg per kilogram of bodyweight, 0.4 mg per kilogram of body weight, 0.5 mg per kilogram of bodyweight, 1 mg per kilogram of body weight, 2 mg per kilogram of bodyweight, 3 mg per kilogram of body weight, 4 mg per kilogram of bodyweight, or 5 mg per kilogram of body weight can be administered. In oneembodiment, the dose is about 1 mg to about 20 mg per kilogram of bodyweight.

The invention also includes other dosages when employing a dosingschedule of the invention. For example in accordance with a dosingschedule of the invention, between about 0.1 mg and about 50 mg perkilogram of body weight is administered to a patient.

In some embodiments, about 0.5 to about 50 mg of exogenous LAL areadministered, e.g. to a patient with Wolman disease at the age between 1month and 24 months. In one embodiment the patient is less than 1 yearof age. In another embodiment, the patient is less than 2 years of age.In some embodiments, about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4mg, about 0.5 mg, about 1 mg, about 2 mg, about 3 mg, about 5 mg, about10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg,about 40 mg, or about 45 mg of exogenous LAL is administered to thepatient with Wolman disease. In some embodiments, about 0.5 to about 30mg, about 0.5 to about 20 mg, about 0.5 to about 10 mg, or about 0.5 toabout 5 mg are administered to the patient with Wolman disease. In someembodiments, about 1 to about 30 mg, about 1 to about 20 mg, about 1 toabout 10 mg, or about 1 to about 5 mg are administered.

In some embodiments, about 1 mg to about 350 mg of exogenous LAL areadministered, e.g. to a patient diagnosed with CESD. Thus, in someembodiments, about 1, 5, 10, 25, 50, 75, 100, 125, 150, 175, 200, 225,250, 275, 300, 325, or 350 mg of exogenous LAL is administered to thepatient with CESD. In some embodiments, about 5 to about 350 mg, about 5to about 300 mg, about 5 to about 250 mg, or about 5 to about 200 mg areadministered to the patient with CESD. In some embodiments, about 10 toabout 350 mg, about 10 to about 300, about 10 to about 250, or about 10to about 200 mg are administered to the patient with CESD.

Combination Treatments

The therapeutic proteins disclosed herein can be used in combinationwith other therapeutic agents. The invention provides for a pretreatmentprocedure to minimize or prevent any potential anaphylactic reactionsthat can be incurred by administration of exogenous LAL in accordancewith the invention. In one embodiment, to pretreat a potentialanaphylactic reaction, an H-1 receptor antagonist, also known as anantihistamine (e.g., diphenhydramine) is administered to the patient. Inone embodiment, the H-1 receptor antagonist is administered in a dose ofabout 1 mg to about 10 mg per kilogram of body weight. For example, anantihistamine can be administered in a dose of about 5 mg per kilogram.Administration of the antihistamine can be prior to the administrationof exogenous LAL in accordance with the invention. In one embodiment,the H-1 receptor antagonist is administered about 10 to about 90minutes, for example, about 30 to about 60 minutes prior to theadministration of exogenous LAL. The H-1 receptor antagonist can beadministered using an ambulatory system connected to a vascular accessport. In one embodiment, the antihistamine is administered about 90minutes prior to the administration of exogenous LAL. In one embodiment,the antihistamine is administered between about 10 and about 60 minutesprior to the administration of exogenous LAL. In another embodiment, theantihistamine is administered between about 20 and about 40 minutesprior to administering exogenous LAL. For example, the antihistamine canbe administered 20, 25, 30, 35, or 40 minutes prior to theadministration of exogenous LAL. In one embodiment, the antihistamineadministered is diphenhydramine. Any useful antihistamine can be used.Such antihistamines include, without limitation, clemastine, doxylamine,loratidine, desloratidine, fexofenadine, pheniramine, cetirizine,ebastine, promethazine, chlorpheniramine, levocetirizine, olopatadine,quetiapine, meclizine, dimenhydrinate, embramine, dimethidene, anddexchloropheniramine.

In one embodiment, the antihistamine is administered in a dose ofbetween about 0.1 mg and about 10 mg per kilogram of body weight. In oneembodiment, the antihistamine is administered in a dose between about 1mg and about 5 mg per kilogram of body weight. For example the dose canbe 1 mg, 2 mg, 3 mg, 4 mg, or 5 mg per kilogram of body weight. Theantihistamine can be administered by any useful method. In oneembodiment, the antihistamine is administered intravenously. In anotherembodiment, the antihistamine is administered in pharmaceuticallyacceptable capsules.

In another embodiment, with reference to intravenous infusion, thepotential for anaphylactic reactions can be reduced by administering theinfusions using a ramp-up protocol. In this context, a ramp-up protocolrefers to slowly increasing the rate of the infusion over the course ofthe infusion in order to desensitize the patient to the infusion of themedication.

Immunosuppresants such as, but not limited to, antihistamines,corticosteroids, sirolimus, voclosporin, ciclosporin, methotrexate, IL-2receptor directed antibodies, T-cell receptor directed antibodies,TNF-alpha directed antibodies or fusion proteins (e.g., infliximab,etanercept, or adalimumab), CTLA-4-Ig (e.g., abatacept), anti-OX-40antibodies can also be administered before, during, or after exogenousLAL administration, for example, if an anaphylactic reaction or adverseimmune response is expected or experienced by a patient.

The invention also encompasses therapy involving administration ofexogenous LAL-containing compositions in combination with one or morecholesterol lowering agents (e.g., HMG-CoA reductase inhibitors).Non-limiting examples of such agents include: atorvastatin (Lipitor® andTorvast®), fluvastatin (Lescol®), lovastatin (Mevacor®, Altocor®,Altoprev®), pitavastatin (Livalo®, Pitava®), pravastatin (Pravachol®,Selektine®, Lipostat®), rosuvastatin (Crestor®), and simvastatin(Zocor®, Lipex).

Effects of Exogenous LAL

The present invention provides for a correction or normalization ofdisease-related symptoms following treatment with exogenous LAL. Theclinical progression (i.e., improvement of the condition) in response toexogenous LAL can be monitored by any useful method or procedure.

In some embodiments, administration of exogenous LAL is sufficient toachieve a Cmax of about 200 ng/mL to about 1,500 ng/mL. In someembodiments, administration of exogenous LAL is sufficient to achieve aCmax of about 200 ng/mL to about 1,000 ng/mL. In some embodiments,administration of exogenous LAL is sufficient to achieve a Cmax of about200 ng/mL to about 800 ng/mL. In some embodiments, administration ofexogenous LAL is sufficient to achieve a Cmax of about 200 ng/mL, about300 ng/mL, about 400 ng/mL, about 500 ng/mL, about 600 ng/mL, about 700ng/mL, about 800 ng/mL, about 900 ng/mL, about 1,000 ng/mL, about 1,250ng/mL, or about 1,500 ng/mL. In some embodiments, Cmax is reached duringinfusion.

In some embodiments, administration of exogenous LAL is sufficient toachieve a LAL half-life (t_(1/2)) that is less than 40 minutes. In someembodiments, administration of exogenous LAL is sufficient to achieve aLAL half-life (t_(1/2)) that is less than 30 minutes. In someembodiments, administration of exogenous LAL is sufficient to achieve aLAL half-life (t_(1/2)) that is less than 20 minutes. In someembodiments, administration of exogenous LAL is sufficient to achieve aLAL half-life (t_(1/2)) that is less than 15 minutes. In someembodiments, administration of exogenous LAL is sufficient to achieve aLAL half-life (t_(1/2)) that is less than 10 minutes. In someembodiments, administration of exogenous LAL is sufficient to achieve aLAL half-life (t_(1/2)) of about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, 20, 25, 30, 35, or 40 minutes.

In some embodiments, exogenous LAL increases LAL activity in a patient.LAL activity can be increased, for example, in liver, spleen, lymphnodes, aorta, peripheral blood leukocytes, and/or skin fibroblasts. Insome embodiments, LAL activity is measured in extracts of lymphocytesisolated from blood samples.

Exogenous LAL can increase LAL activity to at least about 1.5, about 2,about 2.5, about 3, about 4, about 5, about 6, about 7, about 8, about9, about 10, about 15, or about 20 times the activity prior to LALadministration. Exogenous LAL can increase LAL activity to at leastabout 10, about 11, about 12, about 13, about 14, about 15, about 16,about 17, about 18, about 19, about 20 times the activity prior to LALadministration. LAL activity can be assessed using methods known in theart including, for example, assays using cholesteryl [1-¹⁴C]oleate,triolein (glycerol tri [1-¹⁴C]oleate), p-nitropheny myristate or 4-MUO(4-methylumbelliferyl oleate) substrates.

In one embodiment, organ and tissue volume and characterization isemployed to determine the improvement of the condition followingadministration of exogenous LAL in accordance with the invention.

In one embodiment, clinical progression in liver function/injuryfollowing administration of exogenous LAL is monitored by thequantification of blood transaminases such as aspartic acidaminotransferase (AST) and/or alanine transaminase (ALT), and/or otherbiomarkers, such as albumin, alkaline phosphatase, and bilirubin (directand total), over time.

In one embodiment, clinical progression is monitored using imagingtechnology. For example, and without limitation, the imaging technologyused can be ultrasound, CT scanning, magnetic resonance imaging, andnuclear magnetic resonance spectroscopy.

In some embodiments, administration of exogenous LAL with the dosesdescribed herein is sufficient to restore growth and/or increase bodyweight in human patients. Administration of exogenous LAL can alsoincrease the rate of growth (i.e., body weight increase) in an infant orchild patient suffering from early onset LAL deficiency. For example,administration of exogenous LAL can increase the rate of body weightincrease by at least about 10%, about 20%, about 30%, about 40%, about50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 200%,about 300%, about 400%, or about 500% of the growth rate/velocity seenprior to the administration. In some embodiments, administration ofexogenous LAL restores normal growth rate in a child patient sufferingfrom early onset LAL deficiency (e.g., Wolman Disease) whose age isbetween about 1 month and about 24 months. “Normal” in this contextrefers to normal growth rate for the patient being treated as determinedby a practitioner of ordinary skill in the art of medical sciences.

In one embodiment, for example with reference to WD and CESD or otherLAL deficiencies, hepatomegaly is reversed significantly with liver sizereturning to a size of which is within about 1% to about 60% larger thanthat of normal. “Normal” in this context refers to a liver of normalsize for the patient being treated as determined by a practitioner ofordinary skill in the art of medical sciences. In one embodiment, liversize is reduced to between about 1% and about 50% greater than normal.In another embodiment, liver size is reduced to between about 1% andabout 40% greater than normal. In one embodiment, liver size is reducedto between about 1% and about 30% greater than normal. In anotherembodiment, liver size is reduced to between about 1% and about 20%greater than normal. In another embodiment, liver size is reduced tobetween about 10% and about 20% greater than normal. For example, theliver can be 10%, 11%, 12% 13% 14%, 15%, 16%, 17%, 18%, 19%, or 20%larger than the normal size. In still another embodiment, liver size isreduced to between about 0% and about 10% greater than normal. Forexample, the liver can be 0%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10%larger than the normal size of the liver.

Treatment with exogenous LAL can also improve liver function. Thus, insome embodiments, treatment with exogenous LAL is sufficient to restorenormal liver function and/or normalize liver tests. In some embodiments,treatment with exogenous LAL is sufficient to decrease serum levels ofliver transaminases, e.g., by at least about 20%, about 30%, about 40%,about 50%, about 60%, about 70%, about 80%, and/or to at least about90%. In one embodiment, treatment with exogenous LAL is sufficient todecrease serum levels of liver transaminases by at least about 40%. Inone embodiment, treatment with exogenous LAL is sufficient to decreaseserum levels of liver transaminases by at least about 50%. In oneembodiment, treatment with exogenous LAL is sufficient to decrease serumlevels of liver transaminases by at least about 60%. In one embodiment,treatment with exogenous LAL is sufficient to decrease serum levels ofliver transaminases by at least about 70%. In one embodiment, treatmentwith exogenous LAL is sufficient to decrease serum levels of livertransaminases by at least about 80%. In one embodiment, treatment withexogenous LAL is sufficient to decrease serum levels of livertransaminases by at least about 90%.

In some embodiments, the liver transaminase is alanine aminotransferase(ALT). In one embodiment, administration of exogenous LAL is sufficientto reduce serum ALT. For example, administration of exogenous LAL canreduce serum ALT, e.g., by at least about 50%, 60%, 70%, 80% or 90%.Serum ALT level can serve an indication of liver injury. Thus, thepresent invention also contemplates methods of reducing liver injury ina human patient suffering from LAL deficiency by administering aneffective amount of exogenous LAL to reduce serum ALT.

In some embodiments, the liver transaminase is serum aspartatetransaminase (AST). In one embodiment, administration of exogenous LALis sufficient to reduce serum AST. For example, administration ofexogenous LAL can reduce serum AST, e.g., by at least about 50%, 60%,70%, 80% or 90%. Serum AST level can serve an indication of liverinjury. Accordingly, the present invention also contemplates a method ofreducing liver injury in a patient suffering from LAL deficiency byadministering an effective amount of exogenous LAL to reduce serum AST.

In some embodiments, treatment with exogenous LAL can decrease serumferritin levels. Thus, in some embodiments, treatment with exogenous LALis sufficient to decrease serum ferritin, e.g., by at least about 20%,30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% as compared to pretreatmentlevels. In one embodiment, treatment with exogenous LAL is sufficient todecrease serum levels of ferritin by at least 50%. In yet anotherembodiment, treatment with exogenous LAL is sufficient to decrease serumlevels of ferritin by at least about 60%. In one embodiment, treatmentwith exogenous LAL is sufficient to decrease serum levels of ferritin byat least about 70%. In one embodiment, treatment with exogenous LAL issufficient to decrease serum levels of ferritin by at least about 80%.In one embodiment, treatment with exogenous LAL is sufficient todecrease serum levels of ferritin by at least about 90%. In oneembodiment, treatment with exogenous LAL is sufficient to decrease serumlevels of ferritin by at least about 95%.

In one embodiment, for example, with reference to Wolman Disease andCESD or other LAL deficiencies, splenomegaly is reversed significantlywith spleen size returning to a size of which is within about 1% toabout 60% larger than that of normal. “Normal” in this context refers toa spleen of normal size for the patient being studied as determined by apractitioner of ordinary skill in the art of medical sciences. In oneembodiment, spleen size is reduced to between about 1% and about 50%greater than normal. In another embodiment, spleen size is reduced tobetween about 1% and about 40% greater than normal. In one embodiment,spleen size is reduced to between about 1% and about 30% greater thannormal. In another embodiment, spleen size is reduced to between about1% and about 20% greater than normal. In another embodiment, spleen sizeis reduced to between about 10% and about 20% greater than normal. Forexample, the spleen can be 10%, 11%, 12% 13% 14%, 15%, 16%, 17%, 18%,19%, or 20% larger than the normal size. In still another embodiment,spleen size is reduced to between about 0% and about 10% greater thannormal. For example, the spleen can be 0%, 1%, 2%, 3%, 4%, 5%, 6%, 7%,8%, 9%, or 10% larger than the normal size of the spleen.

In one embodiment, administration of exogenous LAL is sufficient todecrease lymphadenopathy (i.e., enlarged lymph nodes). Thus, in someembodiments, lymph nodes are reduced to about a size of which is withinabout 1% to about 60% larger than that of normal. “Normal” in thiscontext refers to lymph nodes of normal size for the patient beingstudied as determined by a practitioner of ordinary skill in the art ofmedical sciences. In one embodiment, lymph node size is reduced to about1% to about 50% greater than normal. In another embodiment, lymph nodesize is reduced to about 1% to about 40% greater than normal. In oneembodiment, lymph node size is reduced to about 1% to about 30% greaterthan normal. In another embodiment, lymph node size is reduced to about1% to about 20% greater than normal. In another embodiment, lymph nodesize is reduced to about 10% to about 20% greater than normal. Forexample, the lymph nodes can be 10%, 11%, 12% 13% 14%, 15%, 16%, 17%,18%, 19%, or 20% larger than the normal size. In still anotherembodiment, lymph node size is reduced to about 0% to about 10% greaterthan normal. For example, the lymph node can be 0%, 1%, 2%, 3%, 4%, 5%,6%, 7%, 8%, 9%, or 10% larger than the normal size of the lymph nodes.In another embodiment, lipid analysis is performed to monitorimprovement of the condition. For example, lipid analysis can be done toevaluate the therapeutic effect of the exogenous LAL. The lipid analysiscan be conducted on a tissue sample of a patient (e.g., a blood sample,liver biopsy sample) by any useful method such as, but not limited tohigh-performance liquid chromatography, gas chromatography, massspectroscopy, or thin-layer chromatography, or any combination thereofas deemed appropriate by one skilled in the art. In one embodiment,lipid analyses performed in accordance with the invention, demonstratethe levels of total cholesterol, triglycerides, low-densitylipoproteins, high-density lipoproteins and/or cholestryl ester.

In one embodiment, for example, with reference to Wolman Disease andCESD or other LAL deficiencies, lipid analysis of a patient treated inaccordance with the invention shows a normalization of lipidconcentrations in the liver, spleen, intestine, lymph nodes, and/oraorta as can determined by a practitioner of ordinary skill in the fieldof medical sciences.

Lipid levels can be assessed using plasma lipid analyses or tissue lipidanalysis. In plasma lipid analysis, blood plasma can be collected, andtotal plasma free cholesterol levels can be measured using, for examplecolormetric assays with a COD-PAP kit (Wako Chemicals), total plasmatriglycerides can be measured using, for example, a Triglycerides/GB kit(Boehringer Mannheim), and/or total plasma cholesterol can be determinedusing a Cholesterol/HP kit (Boehringer Mannheim). In tissue lipidanalysis, lipids can be extracted, for example, from liver, spleen,and/or small intestine samples (e.g., using the Folch method provided inFolch et al. J. Biol. Chem 226: 497-505 (1957)). Total tissuecholesterol concentrations can be measured, for example, usingO-phthalaldehyde.

In some embodiments, administration of exogenous LAL is sufficient toincrease nutrient absorption. In one embodiment, administration ofexogenous LAL increases nutrient absorption as measured by levels ofserum alpha tocopherol, 250H vitamin D, serum retinol, didehydroretinol,or transthyretin.

In some embodiments, for example with reference to WD and CESD or otherLAL deficiencies, administration of exogenous LAL is sufficient toincrease serum hemoglobin levels (Hb). In one embodiment, the hemoglobinlevel is increased at least about 10% or about 20% as compared to thatobserved prior to administration with exogenous LAL.

In some embodiments, the exogenous LAL can be administered using methodsto minimize side effects. For example, the administration of exogenousLAL can minimize immune responses to the exogenous LAL.

LAL and Pharmaceutical Compositions Comprising Exogenous LAL

The present invention encompasses treating any of the LALdeficiency-related conditions described herein and other conditions notpreviously mentioned, but which would benefit from the treatment.Exogenous LAL employed in accordance with the invention includesrecombinant LAL which can be produced in any useful protein expressionsystem including, without limitation, cell culture (e.g., CHO cells, COScells), bacteria such as E. coli, transgenic animals such as mammals andavians (e.g., chickens, duck, and turkey) and in plant systems (e.g.,duck weed and tobacco plants). One aspect of the invention relates torecombinant LAL produced in accordance with U.S. Pat. No. 7,524,626,issued Oct. 3, 2006; U.S. patent application Ser. No. 11/973,853, filedOct. 10, 2007; Ser. No. 11/978,360, filed Oct. 29, 2007; and Ser. No.12/319,396, filed Jan. 7, 2009, the disclosures of which areincorporated in their entirety herein by reference. One aspect of theinvention relates to recombinant LAL produced as described in Du et al.,(2005) Am. 1 Hum. Genet. 77: 1061-1074, and Du et al., (2008) J. LipidRes., 49: 1646-1657, the disclosures of which are incorporated in theirentirety herein by reference. In one useful embodiment, the exogenousLAL is produced in the oviduct of a transgenic avian (e.g., a transgenicchicken), for example, according to a method described inPCT/US2011/033699, filed Apr. 23, 2011, which is incorporated byreference herein in its entirety. In some embodiments, the recombinantLAL is produced in an avian cell line. In some embodiments, therecombinant LAL is produced in a mammalian (e.g., a human) cell line.

In one embodiment, exogenous lysosomal acid lipase used in accordancewith the invention contains glycans having substantialN-acetylglucosamine (GlcNAc) and mannose terminated N-linked structures.GlcNAc and mannose terminated glycans on exogenous LAL can bespecifically recognized and internalized by macrophages and fibroblast.Mannose-6-phosphate (M6P), which can target proteins to theGlcNAc/mannose receptors which are expressed on cells implicated inconditions treatable by exogenous LAL administration, is also typicallypresent on exogenous LAL used in accordance with the invention.

Typically, the exogenous LAL of the invention discussed and disclosedherein is human LAL. In one embodiment, the exogenous LAL has the aminoacid sequence provided in Genbank RefSeq NM_000235.2). In oneembodiment, the mature exogenous LAL has the amino acid sequence:

(SEQ ID NO: 1) SGGKLTAVDPETNMNVSEIISYWGFPSEEYLVETEDGYILCLNRIPHGRKNHSDKGPKPVVFLQHGLLADSSNWVTNLANSSLGFILADAGFDVWMGNSRGNTWSRKHKTLSVSQDEFWAFSYDEMAKYDLPASINFILNKTGQEQVYYVGHSQGTTIGFIAFSQIPELAKRIKMFFALGPVASVAFCTSPMAKLGRLPDHLIKDLFGDKEFLPQSAFLKWLGTHVCTHVILKELCGNLCFLLCGFNERNLNMSRVDVYTTHSPAGTSVQNMLHWSQAVKFQKFQAFDWGSSAKNYFHYNQSYPPTYNVKDMLVPTAVWSGGHDWLADVYDVNILLTQITNLVFHESIPEWEHLDFIWGLDAPWRLYNKIINLMRKYQ

In some embodiments, the exogenous LAL comprises amino acids 1-378 ofSEQ ID NO:1, amino acids 3-378 of SEQ ID NO:1, amino acids 6-378 of SEQID NO:1, or amino acids 7-378 of SEQ ID NO:1. In some embodiments, theexogenous LAL comprises a mixture of at least two polypeptides selectedfrom the group consisting of amino acids 1-378 of SEQ ID NO:1, aminoacids 3-378 of SEQ ID NO:1, amino acids 6-378 of SEQ ID NO:1, and aminoacids 7-378 of SEQ ID NO:1. In some embodiments, the exogenous LALcomprises a mixture of a polypeptide comprising amino acids 1-378 of SEQID NO:1, a polypeptide comprising amino acids 3-378 of SEQ ID NO:1, anda polypeptide comprising amino acids 6-378 of SEQ ID NO:1. In someembodiments, the exogenous LAL comprises a polypeptide that is identicalto amino acids 1-378 of SEQ ID NO:1, amino acids 3-378 of SEQ ID NO:1,amino acids 6-378 of SEQ ID NO:1, or amino acids 7-378 of SEQ ID NO:1.In other embodiments, the exogenous LAL comprises a polypeptide that isat least about 70%, about 75%, about 80%, about 85%, about 90%, about95%, about 96%, about 97%, about 98%, or about 99% identical to aminoacids 1-378 of SEQ ID NO:1, amino acids 3-378 of SEQ ID NO:1, aminoacids 6-378 of SEQ ID NO:1, or amino acids 7-378 of SEQ ID NO:1. In someembodiments, the exogenous LAL comprises a polypeptide that is afunctional fragment of SEQ ID NO:1 or is at least about 70%, about 75%,about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about98%, or about 99% identical a functional fragment of SEQ ID NO:1.

In some embodiments the exogenous LAL is a recombinant LAL proteindescribed in PCT/US2011/033699, filed Apr. 23, 2011, which isincorporated by reference herein in its entirety.

It is recognized that amino acid positions that are not identical oftendiffer by conservative amino acid substitutions, where amino acidresidues are substituted for other amino acid residues with similarchemical properties (e.g., charge or hydrophobicity) and therefore donot change the functional properties of the molecule. Where sequencesdiffer in conservative substitutions, the percent sequence identity canbe adjusted upwards to correct for the conservative nature of thesubstitution. Means for making this adjustment are well known to thoseof skill in the art. The scoring of conservative substitutions can becalculated according to, for example, the algorithm of Meyers & Millers,Computer Applic. Biol. Sci. 4:11-17 (1988).

A “comparison window” refers to a segment of contiguous positions, suchas between about 25 and about 400 positions, or between about 50 to 200positions, or between about 100 and 150 positions, over which a sequencemay be compared to a reference sequence of the same number of contiguouspositions after the two sequences are optimally aligned. Methods ofalignment of sequences for comparison are well known in the art. Optimalalignment of sequences for comparison can be conducted, for example, bya local homology algorithm (Smith & Waterman, Adv. Appl. Math. 2:482(1981), by a global alignment algorithm (Needleman & Wunsch, J. Mol.Biol. 48:443 (1970), by search for similarity methods (Pearson & Lipman,Proc. Natl. Acad. Sci. U.S.A. 85:2444 (1988); Altschul et al., Nucl.Acids Res. 25:3389-402 (1997), by computerized implementations of thesealgorithms (e.g., GAP, BESTFIT, FASTA, and BLAST in the WisconsinGenetics Software Package, Genetics Computer Group, 575 Science Dr.,Madison, Wis.), typically using the default settings, or by manualalignment and visual inspection (see, e.g., Current Protocols inMolecular Biology, Ausubel et al. (eds.), 1994). For example, BLASTprotein searches can be performed using the XBLAST program, score=50,wordlength=3 to obtain amino acid sequences that are more than 80%identical to the amino acid sequence of SEQ ID NO:1 or a fragmentthereof.

One example of a useful algorithm implementation is PILEUP. PILEUPcreates a multiple sequence alignment from a group of related sequencesusing progressive pairwise alignments. It can also plot a dendrogramshowing the clustering relationships used to create the alignment.PILEUP uses a simplification of the progressive alignment method of Feng& Doolittle, J. Mol. Evol. 35:351-360 (1987). The method used is similarto the method described by Higgins & Sharp, CABIOS 5:151-3 (1989). Themultiple alignment procedure begins with the pairwise alignment of thetwo most similar sequences, producing a cluster of two alignedsequences. This cluster can then be aligned to the next most relatedsequence or cluster of aligned sequences. Two clusters of sequences canbe aligned by a simple extension of the pairwise alignment of twoindividual sequences. A series of such pairwise alignments that includesincreasingly dissimilar sequences and clusters of sequences at eachiteration produces the final alignment.

In some embodiments, exogenous LAL polypeptides of the invention includevariants of the wild-type sequences. These variants fall into one ormore of three classes: substitutional, insertional, or deletionalvariants. These variants can be naturally occurring allelic orinterspecies variants or they can be prepared by site-specificmutagenesis of nucleotides in the DNA encoding protein. Site-specificmutagenesis can be performed using cassette or PCR mutagenesis or othertechniques well known in the art to produce DNA encoding the variantand, thereafter, expressing the DNA in recombinant cell culture. Varianttarget protein fragments having up to about 100-150 amino acid residuescan be prepared by in vitro synthesis using established techniques.Conservative substitution tables providing functionally similar aminoacids are well known in the art (Henikoff & Henikoff, Proc. Natl. Acad.Sci. U.S.A. 89:10915-10919 (1992)).

Amino acid substitutions are typically of single residues. Insertionsusually will be on the order of from about 1 to about 20 amino acids,although considerably longer insertions can be tolerated. Deletionsrange from about 1 to about 20 residues, although in some cases,deletions can be much longer. Substitutions, deletions, and insertionsor any combinations thereof can be used to arrive at a final derivative.

In some embodiments, the exogenous LAL has a specific activity of atleast about 100 U/mg. In some embodiments, the exogenous LAL has aspecific activity of at least about 200 U/mg. In some embodiments, theexogenous LAL has a specific activity of at least about 250 U/mg. Insome embodiments, the exogenous LAL has a specific activity of about 100to about 1,000 U/mg. In some embodiments, the exogenous LAL has aspecific activity of about 100 to about 500 U/mg. In some embodiments,the exogenous LAL has a specific activity of about 100 to about 350U/mg. In some embodiments, the exogenous LAL has a specific activity ofabout 200 to about 350 U/mg. In some embodiments, the exogenous LAL hasa specific activity of about 250 to about 350 U/mg. In some embodiments,the exogenous LAL has a specific activity of about 250 U/mg. In someembodiments, the exogenous LAL has a specific activity of about 275U/mg. In some embodiments, the exogenous LAL has a specific activity ofabout 300 U/mg. Human LAL has 6 potential sites in its amino acidsequence for N-linked glycosylation: Asn36, Asn72, Asn101, Asn161,Asn273, and Asn321 as set forth in SEQ ID NO:1. In some embodiments, atleast 1, 2, 3, 4, or 5 of the 1-linked glycosylation sites areglycosylated. In some embodiments all six glycosylation sites areglycosylated. In some embodiments, Asn36, Asn101, Asn161, Asn273, andAsn321 are glycosylated. In some embodiments, Asn36, Asn101, Asn161,Asn273, and Asn321 are glycosylated, and Asn72 is not glycosylated. Insome embodiments, the N-glycan structures comprise bi, tri-, andtetraantennary structures with N-acetylglucosamine (GlcNAc), mannose,and/or mannose-6-phosphate (M6P). In some embodiments, the exogenous LALcomprises M6P-modified N-glycans at Asn101, Asn161, and Asn273. In someembodiments, the exogenous LAL does not comprise O-linked glycans. Insome embodiments, the exogenous LAL does not comprise sialic acid. Insome embodiments, the exogenous LAL has a glycosylation pattern asdescribed in PCT/US2011/033699, filed Apr. 23, 2011, which isincorporated by reference herein in its entirety.

In some embodiments, the molecular weight of the exogenous LAL is about55 kD.

In certain embodiments, a subject may be treated with a nucleic acidmolecule encoding exogenous LAL, e.g., in a vector. Doses for nucleicacids encoding polypeptides range from about 10 ng to 1 g, 100 ng to 100mg, 1 μg to 10 mg, or 30-300 μg DNA per patient. Doses for infectiousviral vectors vary from 10-100, or more, virions per dose.

In some embodiments of the present invention exogenous LAL isadministered in a treatment method that includes: (1) transforming ortransfecting an implantable host cell with a nucleic acid, e.g., avector, that expresses LAL or an active fragment, variant, or derivativethereof; and (2) implanting the transformed host cell into a mammal. Insome embodiments of the invention, the implantable host cell is removedfrom a mammal, temporarily cultured, transformed or transfected with anisolated nucleic acid encoding exogenous LAL, and implanted back intothe same mammal from which it was removed. The cell can be, but is notrequired to be, removed from the same site at which it is implanted.Such embodiments, sometimes known as ex vivo gene therapy, can provide acontinuous supply of the exogenous LAL polypeptide, for a limited periodof time.

While it is possible for the therapeutic protein provided for in thisinvention, recombinant LAL, to be administered in raw form, it ispreferable to administer the therapeutic protein as part of apharmaceutical formulation.

The invention thus further provides pharmaceutical formulationscomprising avian derived glycosylated therapeutic proteins or apharmaceutically acceptable derivative thereof together with one or morepharmaceutically acceptable carriers thereof and, optionally, othertherapeutic and/or prophylactic ingredients and methods of administeringsuch pharmaceutical formulations. The invention also providespharmaceutical formulations comprising mammalian derived glycosylatedtherapeutic proteins or a pharmaceutically acceptable derivative thereoftogether with one or more pharmaceutically acceptable carriers thereofand, optionally, other therapeutic and/or prophylactic ingredients andmethods of administering such pharmaceutical formulations.

The carriers) must be “acceptable” in the sense of being compatible withthe other ingredients of the formulation and not deleterious to therecipient thereof. Methods of treating a patient (e.g., quantity ofpharmaceutical protein administered, frequency of administration andduration of treatment period) using pharmaceutical compositions of theinvention can be determined using standard methodologies known tophysicians of skill in the art.

Pharmaceutical formulations include those suitable for oral, rectal,nasal, topical (including buccal and sub-lingual), vaginal orparenteral. The pharmaceutical formulations include those suitable foradministration by injection including intramuscular, sub-cutaneous andintravenous administration. The pharmaceutical formulations also includethose for administration by inhalation or insufflation. The formulationscan, where appropriate, be conveniently presented in discrete dosageunits and can be prepared by any of the methods well known in the art ofpharmacy. The methods of producing the pharmaceutical formulationstypically include the step of bringing the therapeutic proteins intoassociation with liquid carriers or finely divided solid carriers orboth and then, if necessary, shaping the product into the desiredformulation.

Pharmaceutical formulations suitable for oral administration canconveniently be presented as discrete units such as capsules, cachets ortablets each containing a predetermined amount of the active ingredient;as a powder or granules; as a solution; as a suspension; or as anemulsion. The active ingredient can also be presented as a bolus,electuary or paste. Tablets and capsules for oral administration cancontain conventional excipients such as binding agents, fillers,lubricants, disintegrants, or wetting agents. The tablets can be coatedaccording to methods well known in the art. Oral liquid preparations canbe in the form of, for example, aqueous or oily suspensions, solutions,emulsions, syrups or elixirs, or can be presented as a dry product forconstitution with water or other suitable vehicle before use. Suchliquid preparations can contain conventional additives such assuspending agents, emulsifying agents, non-aqueous vehicles (which caninclude edible oils) or preservatives.

Therapeutic proteins of the invention can also be formulated forparenteral administration (e.g., by injection, for example bolusinjection or continuous infusion) and can be presented in unit dose formin ampoules, pre-filled syringes, small volume infusion or in multi-dosecontainers with an added preservative. The therapeutic proteins can beinjected by, for example, subcutaneous injections, intramuscularinjections, and intravenous (IV) infusions or injections. In oneembodiment, the exogenous LAL is administered intravenously by IVinfusion by any useful method. In one example, the exogenous LAL can beadministered by intravenous infusion through a peripheral line. Inanother example, the exogenous LAL can be administered by intravenousinfusion through a peripherally inserted central catheter. In anotherexample, the exogenous LAL can be administered by intravenous infusionfacilitated by an ambulatory infusion machine attached to a venousvascular access port. In one embodiment, of intravenous infusion, themedication is administered over a period of 1 to 8 hours depending onthe amount of medication to be infused and the patient's previousinfusion-related reaction history, as determined by a physician skilledin the art. In another embodiment, the exogenous LAL is administeredintravenously by IV injection. In another embodiment, the exogenous LALcan be administered via intraperitoneal injection. In still anotherembodiment, the exogenous LAL is administered via a pharmaceuticallyacceptable capsule of the therapeutic protein. For example, the capsulecan be an enteric-coated gelatin capsule.

In some embodiments, the therapeutic proteins are administered byinfusion, and the infusion can occur over an extended time period, forexample, 30 minutes to 10 hours. Thus, the infusion can occur, forexample, over a period of about 1 hour, about 2 hours, about 3 hours,about 4 hours, or about 5 hours. The infusion can also occur at variousrates. Thus, for example, the infusion rate can be about 1 mL per hourto about 20 mL per hour. In some embodiments, the infusion rate is 5 mLto 10 mL per hour. In one embodiment, the infusion rate is 1, 2, 3, 4,5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 mL per hour.In one embodiment, the infusion rate is 0.1 to 5 mg/kg/hr. In oneembodiment, the infusion rate is about 0.1, about 0.2, about 0.3, about0.5, about 1.0, about 1.5, about 2.0, or about 3 mg/kg/hr,

The therapeutic proteins can take such forms as suspensions, solutions,or emulsions in oily or aqueous vehicles, and can contain formulatoryagents such as suspending, stabilizing and/or dispersing agents. Thetherapeutic proteins can be in powder form, obtained by asepticisolation of sterile solid or by lyophilization from solution, forconstitution with a suitable vehicle, e.g., sterile, pyrogen-free water,before use.

For topical administration to the epidermis, the therapeutic proteinscan be formulated as ointments, creams or lotions, or as a transdermalpatch. Ointments and creams can, for example, be formulated with anaqueous or oily base with the addition of suitable thickening and/orgelling agents. Lotions can be formulated with an aqueous or oily baseand will in general also contain one or more emulsifying agents,stabilizing agents, dispersing agents, suspending agents, thickeningagents or coloring agents.

Formulations suitable for topical administration in the mouth includelozenges comprising active ingredient in a flavored base, usuallysucrose and acacia or tragacanth; pastilles comprising the activeingredient in an inert base such as gelatin and glycerin or sucrose andacacia; and mouthwashes comprising the active ingredient in a suitableliquid carrier. Pharmaceutical formulations suitable for rectaladministration wherein the carrier is a solid are most preferablyrepresented as unit dose suppositories. Suitable carriers include cocoabutter and other materials commonly used in the art, and thesuppositories can be conveniently formed by a mixture of the activecompound with the softened or melted carrier(s) followed by chilling andshaping in molds.

Formulations suitable for vaginal administration can be presented aspessaries, tampons, creams, gels, pastes, foams or sprays containing inaddition to the active ingredient, such carriers as are known in the artto be appropriate.

For intra-nasal administration the therapeutic proteins of the inventioncan be used as a liquid spray or dispersible powder or in the form ofdrops.

Drops can be formulated with an aqueous or non-aqueous base alsocomprising one or more dispersing agents, solubilizing agents orsuspending agents. Liquid sprays are conveniently delivered frompressurized packs.

For administration by inhalation, therapeutic proteins according to theinvention can be conveniently delivered from an insufflator, nebulizeror a pressurized pack or other convenient means of delivering an aerosolspray. Pressurized packs can comprise a suitable propellant such asdichlorodifluoromethane, trichlorofluoromethane,dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In thecase of a pressurized aerosol, the dosage unit can be determined byproviding a valve to deliver a metered amount.

For administration by inhalation or insufflation, the therapeuticproteins according to the invention can take the form of a dry powdercomposition, for example a powder mix of the compound and a suitablepowder base such as lactose or starch. The powder composition can bepresented in unit dosage form in, for example, capsules or cartridgesor, e.g., gelatin or blister packs from which the powder can beadministered with the aid of an inhalator or insufflator. When desired,the above described formulations adapted to give sustained release ofthe active ingredient, can be employed.

The pharmaceutical compositions according to the invention can alsocontain other active ingredients such as antimicrobial agents, orpreservatives.

In some embodiments, the concentration of exogenous LAL in thepharmaceutical composition is about 0.5 to about 10 mg/ml. In someembodiments, the concentration of LAL is about 1 to about 5 mg/mL. Insome embodiments, the concentration of LAL is about 1, about 1.5, about2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about5.5, about 6, about 6.5, or about 7.5 mg/mL.

In some embodiments, a pharmaceutical composition comprising exogenousLAL further comprises a buffer. Exemplary buffers include acetate,phosphate, citrate and glutamate buffers. Exemplary buffers also includelithium citrate, sodium citrate, potassium citrate, calcium citrate,lithium lactate, sodium lactate, potassium lactate, calcium lactate,lithium phosphate, sodium phosphate, potassium phosphate, calciumphosphate, lithium maleate, sodium maleate, potassium maleate, calciummaleate, lithium tartarate, sodium tartarate, potassium tartarate,calcium tartarate, lithium succinate, sodium succinate, potassiumsuccinate, calcium succinate, lithium acetate, sodium acetate, potassiumacetate, calcium acetate, and mixtures thereof. In some embodiments, thebuffer is trisodium citrate dihydrate. In some embodiments, the bufferis citric acid monohydrate. In some embodiments, a pharmaceuticalcomposition comprises trisodium citrate dehydrate and citric acidmonohydrate.

In some embodiments, a pharmaceutical composition comprising exogenousLAL further comprises a stabilizer. Exemplary stabilizers includealbumin, trehalose, sugars, amino acids, polyols, cyclodextrins, saltssuch as sodium chloride, magnesium chloride, and calcium chloride,lyoprotectants, and mixtures thereof. In some embodiments, apharmaceutical composition comprises human serum albumin.

In a specific example, recombinant human LAL produced as disclosedherein, is employed in a pharmaceutical formulation wherein each 1milliliter contains exogenous LAL (e.g., 2 mg LAL), trisodium citratedehydrate (e.g., 13.7 mg), citric acid monohydrate (e.g., 1.57 mg), andhuman serum albumin (e.g., 10 mg), and is formulated to an acidic pHsuch as 5.9±0.1. The present invention encompasses any route ofadministration which facilitates the uptake of the exogenous LAL intothe lysosomes of pertinent organs and tissues.

EXAMPLES

The following specific examples are intended to illustrate the inventionand should not be construed as limiting the scope of the claims.

Example 1 Treatment of Early Onset LAL Deficiency (Wolman Disease) byAdministration of Recombinant LAL

At 15 weeks of age, a male infant was admitted to the hospital becauseof poor weight gain since birth (birth weight, 3.88 kg). The infantpresented with vomiting, feeding problems, poor nutritional status,diarrhea, increasing abdominal distension and anemia. The patient wasdiagnosed with Wolman Disease.

At the initial physical examination, the patient weighed 5.62 kg placinghim below the 5^(th) percentile of weight-for-age. Over the next 4 weeksfrom the initial examination at 15 weeks of age and prior to the initialinfusion at 19 weeks of age, the patient failed to gain weight. Theestimated growth velocity was calculated to be less than the 1^(st)percentile for weight-for-age. The abdomen was markedly distended, withsignificant hepatomegaly and splenomegaly. Abdominal ultrasound and CTscan confirmed hepatosplenomegaly and bilateral symmetrically enlargedadrenal glands with calcification. The level of serum alaninetransaminase (ALT) was elevated at 119 U/L (normal 10-50 U/L), as wasthe aspartate transaminase (AST) at 216 U/L (normal 10-45 U/L). Beforetreatment initiation, serum ferritin, a marker of inflammation, wasapproximately 1,500 μg/L (normal 7-144 μg/L). The patient waspersistently anemic prior to treatment with hemoglobin values rangingbetween 7.2 and 8.3 g/dL.

At 19 weeks of age, once weekly IV infusions of rhLAL (SBC-102) wereinitiated at an initial dose of 0.2 mg/kg. The patient was pretreatedwith 1 mg/kg of diphenhydramine approximately 90 minutes prior to theSBC-102 infusion in order to counteract potential infusion reactions.The infusion duration was approximately 4 hours. The infusions were welltolerated, and the patient did not experience any adverse events orinfusion related reactions.

Seven days after the initial infusion, the second infusion wasadministered to the patient. The patient was dosed with 0.3 mg/kg ofSBC-102 approximately for 4 hours and tolerated the infusion withoutexhibiting any signs of adverse events.

Within two weeks of starting treatment, the patient exhibitedsignificant improvement in general well-being, including increasedalertness and responsiveness. The diarrhea and vomiting were stabilized.The patient began to gain weight and exhibited marked reduction in serumtransaminases (e.g., AST and ALT), essentially to normal levels (FIGS.1A and 1B). Growth velocity of the patient rapidly normalized (FIGS. 3and 4). Abdominal distension decreased, corresponding with a reductionin abdominal girth. Liver function tests showed continued improvements(FIGS. 1A and 1B).

At the third visit, the patient received SBC-102 at 0.5 mg/kg. Theinfusions continued to be well tolerated. Clinical status showedcontinued improvement, with a weight gain of 150 g in 7 days, and a 1.5cm increase in arm circumference since the treatment initiation (FIGS. 3and 4). Liver tests were stable, hemoglobin levels increased (10-11g/dL), and ferritin levels continued to decrease (FIG. 2). Alkalinephosphatase was at the low range of normal prior to treatment 137 U/L(normal 110-300 U/L) and increased with treatment (204 U/L). This effectwith SBC-102 administration was consistent with observations made in thepreclinical disease model.

Beginning with the fourth infusion, the patient began receiving a weeklydose of 1.0 mg/kg. Two months following the treatment initiation, thepatient's growth was substantially improved with an estimated growthvelocity close to the 95^(th) percentile. This increase in growthresulted in a gain of 1.25 kg, or 2.79 pounds in 63 days with a weightof 7.21 kg, placing him at the 30 percentile of weight-for-age (FIGS. 3and 4). Both AST and ALT levels decreased rapidly following the firstinfusion.

Three months into the treatment, the AST and ALT were normal. Inaddition to improvements in liver function, a marked reduction inferritin was also observed (FIG. 2).

Over the course of 4 months of treatment, the patient's GI symptomsresolved and the patient's nutritional status was excellent. The patientcontinued to gain weight (FIGS. 3 and 4) and demonstrated physical signsof a normal, healthy infant. The patient continued to tolerate theinfusions without exhibiting any infusion reactions or other sideeffects. The patient received the 21^(st) dose at 1.0 mg/kg as anout-patient.

Example 2 Study Design for Early Onset LAL Deficiency

SBC-102, an rhLAL produced in transgenic Gallus, is administered byweekly IV infusion. The study is designed to evaluate the safety,tolerability and efficacy of two dose regimens of SBC-102 administeredby weekly IV infusions. As such, the main outcome variables in thisstudy determine safety and tolerability of SBC-102 in children withgrowth failure due to LAL Deficiency, and include: vital signs andphysical examination findings; clinical laboratory tests; anti-drugantibodies tests; and use of concomitant medications. Considering that agrowth failure is a universal clinical feature of LAL Deficiency/Wolmanphenotype, a successful therapy for this disorder should be able toaddress the growth failure seen in children affected by LAL Deficiency.Parameters directly related to the child's growth and nutritional statusare evaluated as secondary or exploratory objectives: e.g., incrementalgrowth velocity for weight; weight gain; and rate of linear growth. Thisstudy also investigates the effects of SBC-102 on pharmacodynamicbiomarkers; liver and spleen size; lymphadenopathy; hemoglobin andplatelets; laboratory assessments of liver function and nutrition;abdominal girth, mid-upper arm circumference, and head circumference.This study also describes the preliminary pharmacokinetics of SBC-102 inchildren with growth failure due to LAL Deficiency, including plasmaCmax and estimated clearance.

TABLE 1 Schedule of Assessments: Screening through Week 24 Initial WeekWeek Week Week Week Week Week Week Week Week Week Week Week WeekDiagnosis 1 2 3 4 6 8 10 12 14 16 18 20 22 24 Pre- ±2 ±2 ±2 ±2 ±2 ±2 ±2±2 ±2 ±2 ±2 ±2 ±2 ±2 Assessments infusion days days days days days daysdays days days days days days days days Informed Consent XInclusion/Exclusion X Medical History X Sample for molecular geneticanalysis Dried Blood Spot Health-Related X X X 12-lead ECG ¹ X X^(P)Physical Examination² X X^(P) X^(P) Pregnancy Test³ X X^(P) X^(P) X^(P)X^(P) X^(P) Clinical Laboratory X X^(P) X^(P) X^(P) Liver, Lipid, and XX^(P) X^(P) X^(P) X^(P) Acute Phase⁴ X X^(P) X^(P) X^(P) X^(P) Anti SBC102 X X^(P) X^(P) X^(P) X^(P) X^(P) X^(P) Serum and Urine X X^(P) X^(P)X^(P) X^(P) X^(P) X^(P) Exploratory Biomarker Collection AbdominalMRI/MRS⁶ X X Vital Signs⁷ X X X X X X X X X⁹ X X X X X SBC-102 InfusionX X X X X X X X X¹⁰ X X X X X Adverse Events Continuous ConcomitantContinuous Meds/Therapies ^(P)Pre-infusion ¹ Age appropriate HRQOL.²Physical examination will include measurement of weight (height only atscreening), assessment of liver and spleen size, lymphadenopathy andarterial disease.

Subjects are enrolled in two sequential cohorts of equal size (4subjects each). Dosing is staggered within each cohort and betweencohorts, with dosing commencing with the first subject in the lower-dosecohort (Cohort 1; starting dose 0.35 mg·kg⁻¹). Dosing of additionalsubjects in Cohort 1 and initiation of dosing in the higher-dose cohort(Cohort 2; starting dose 1 mg·kg⁻¹) is based on acceptable safety andtolerability in preceding subjects.

Cohort 1

The first four subjects enrolled in the study constitute Cohort 1. Thefirst subject in this cohort receives a single dose of SBC-102 0.35mg·kg⁻¹ and, if approved for continued dosing based on a safety reviewthrough at least 24 hours post-dose, the subject then receives a seconddose of SBC-102 0.35 mg·kg⁻¹ one week later. After the subject receivesthe second dose of SBC-102, all available safety data are reviewed, atwhich point the acceptability is decided with respect to whether toescalate the dose for the first subject to 1 mg·kg⁻¹ and to initiatedosing of the other subjects in Cohort 1. Dosing of the other 3 subjectsfrom Cohort 1 proceeds in a similar manner. If the safety review doesnot warrant a subject's dose escalation from 0.35 mg·kg⁻¹ to 1 mg·kg⁻¹,but deems it safe for the subject to continue treatment at the startingdose, the subject may continue to receive a dose of 0.35 mg·kg⁻¹. If anysubject in Cohort 1 exhibits a suboptimal response to treatment afterreceiving at least 4 doses of SBC-102 1 mg·kg⁻¹, a further doseescalation to 3 mg·kg⁻¹ is considered.

Cohort 2

Commencement of dosing in Cohort 2 occurs after Cohort 1 is fullyenrolled and the safety reviewed for at least 2 subjects who received 2or more doses of 1 mg·kg⁻¹ SBC-102 in Cohort 1. The last 4 subjectsentering the study are enrolled and dosed in Cohort 2. The first subjectin this cohort receives a single dose of SBC-102 1 mg·kg⁻¹ and, ifapproved for continued dosing based on safety review through at least 24hours post-dose, the subject then receives a second dose of SBC-102 1mg·kg⁻¹ one week later. After the subject receives the second dose ofSBC-102, all available safety data are to be reviewed on theacceptability of the following: escalating the dose for the firstsubject to 3 mg·kg⁻¹ and initiating dosing of the other subjects inCohort 2. Dosing of the other 3 subjects from Cohort 2 is performed in asimilar manner, with a safety review. If the safety reviewer does notapprove a subject's dose escalation from 1 mg·k⁻¹ to 3 mg·kg⁻¹, butdeems it safe for the subject to continue treatment at the startingdose, the subject may continue to receive a dose of 1 mg·kg¹. If thestarting dose of 1 mg·kg⁻¹ is not well-tolerated by a subject, a reduceddose of 0.35 mg·kg⁻¹ may be considered.

The study consists of approximately 22 scheduled visits: Visit 1(screening), Visit 2 (baseline assessment, start of study drug) throughVisit 21 (weekly administration of study drug), Visit 22 (end of studyfollow-up). Given the severity and life threatening nature of earlyonset growth failure due to LAL Deficiency, it is likely that thesesubjects will be hospitalized.

The target population for the study is male and female children withgrowth failure due to LAL Deficiency. A subject is eligible toparticipate in this study if the following criteria are met: (1)subject's parent or legal guardian understands the full nature andpurpose of the study, including possible risks and side effects, andprovides written informed consent/permission prior to any studyprocedures being performed; (2) male or female child with a documenteddecreased LAL activity relative to the normal range of the labperforming the assay or documented result of molecular genetic testingconfirming a diagnosis of LAL Deficiency; and (3) growth failure withonset before 6 months of age.

Safety

The primary safety endpoints includes the incidence of adverse events(AEs) and infusion related reactions (IRRs); changes from baseline invital signs (blood pressure, heart rate, respiratory rate, andtemperature), physical examination findings, and clinical laboratorytests (CBC/hematology, serum chemistry, and urinalysis); use ofconcomitant medications/therapies; and characterization of anti-SBC-102antibodies (ADAs) including seroconversion rate, time to seroconversion,median and peak immunoglobulin G (IgG) ADA titer, and time to peak IgGADA titer.

Efficacy

Efficacy endpoints include: (1) change and/or percent change frombaseline in liver and spleen size (by ultrasound) and liver and spleenvolume and fat content (by magnetic resonance imaging [MRI]); and (2)change from baseline in serum transaminases, serum lipids (totalcholesterol, triglycerides, high density lipoprotein [HDL], and lowdensity lipoprotein [LDL]), hemoglobin and platelet count. Growthparameters, including change from baseline in percentile and z-scores,are also evaluated for subjects ≤18 years of age. These growthparameters are based on Centers for Disease Control (CDC) growth chartsand include weight-for-age (WFA), weight-for-length (WFL),length-for-age (LFA), and head circumference-for-age (HCFA) in subjects<30 months of age and WFA, stature-for-age (SFA; Note: stature refers toa subject's height.), and weight-for-stature (WFS) in subjects ≥36months to 18 years of age, as well as the corresponding growth statusindicators of underweight, wasting, and stunting in all subjects.

Example 3 Physical Assessments of Early Onset LAL Deficiency Patients

Patients who are clinically stable enough to tolerate general anesthesiashould be considered for central line placement for long-term vascularaccess. In subjects receiving general anesthesia and/or sedation forother procedures, a baseline abdominal magnetic resonance imaging (MRI)scan is considered. In the event of new procedures requiring generalanesthesia and/or sedation, a follow-up MRI is considered if it is noearlier than 3 months after the first infusion. Anthropometrics (weight,height, abdominal circumference, mid-upper arm circumference, and headcircumference) are measured. A general physical examination isperformed. A complete physical examination is conducted. The examinationincludes an assessment of the subject's general appearance, skin, head,eyes, ears, nose, and throat, heart, lungs, abdomen, extremities/joints,and neurological status. Every physical examination also includes thefollowing:

-   -   Liver size: A clinical assessment of liver size (palpable/non        palpable and centimeters below costal margin), regularity        (smooth/nodular) and sensitivity (tender/non tender) is made.    -   Spleen size: A clinical assessment of spleen size (palpable/non        palpable and centimeters below costal margin), regularity        (smooth/nodular) and sensitivity (tender/non-tender) is made.    -   Lymphadenopathy: An assessment of the size, location, and        character of any palpable lymph nodes is made. Areas to be        examined include: cephalic (occipital, preauricular,        postauricular, submental, submandibular), cervical, clavicular,        axillary, and inguinal. Any enlarged nodes are characterized as        tender or non-tender.    -   Photograph: A digital image of the subject in supine position        (full length and abdominal close up) is taken.

Hepatic/Spleen Ultrasound and MRI

Abdominal ultrasonography can be performed to measure the liver andspleen size. Abdominal MRI can provide a better quantification of liverand spleen volume, and be considered at baseline and at a visit at least3 months after the first infusion.

Vital Signs

Vital signs include pulse rate, respiratory rate, systolic and diastolicblood pressure and core body temperature (rectal or oral). Assessment ofpulse rate and blood pressure are taken after the subject has been in asupine position. Vital signs are measured at all study visits. On dosingdays, vital signs are recorded pre-infusion, every 15 minutes (±10)during infusion and for 2 hours after the infusion and then every 30minutes (±15) between 2 and 4 hours after the infusion is completed.

Example 4 Laboratory Assessments

The following laboratory assessments are performed as diagnostic testsand efficacy:

-   -   1) CBC/Hematology: White blood cell count, red blood cell count        hemoglobin, hematocrit, mean corpuscular volume (MCV), mean        corpuscular hemoglobin (MCH), mean corpuscular hemoglobin        concentration (MCHC), platelet count, neutrophil, lymphocytes,        monocytes, eosinophils, basophils, peripheral smear for        examination of cell morphology    -   2) Chemistry Panel: Glucose, urea nitrogen, creatinine, sodium,        potassium, chloride, calcium (total and ionized), magnesium,        inorganic phosphorus, total protein, lactate dehydrogenase    -   3) Liver Function Tests: AST/serum glutamic oxaloacetic        transaminase (SGOT), ALT/serum glutamic pyruvic transaminase        (SGPT), alkaline phosphatase, gamma-glutamyl transpeptidase        (GGTP), albumin, bilirubin (direct, total)    -   4) Anti-drug Antibody: Anti-SBC-102 antibody    -   5) Urinalysis: pH, glucose, ketones, blood, protein, nitrite    -   6) Coagulation Studies: leukocytes (microscopic examination can        be done if blood, nitrite and/or leukocytes are abnormal)    -   7) Laboratory Nutrition Assessments: serum alpha        tocopherol:cholesterol ratio, 250H vitamin D, serum retinol,        didehydroretinol, transthyretin, serum ferritin.    -   8) Lipid Panel: Total cholesterol, triglyceride, HDL, LDL    -   9) Genetic Profile

DNA sequences, including both the protein coding sequence and sequencesthat regulate gene transcription, messenger ribonucleic acid (mRNA)stability and the efficiency of protein translation that can beidentified include:

-   -   1. Lysosomal Acid Lipase (LIPA gene)    -   2. Genes coding for other proteins involved in lipid biology        that may contribute to and/or modify the disease phenotype of        LAL Deficiency, e.g. ABCA1    -   3. Genes that may modify susceptibility to any SBC-102

10) Pharmacokinetic Assessments

To reduce risk of iatrogenic anemia, PK sampling may be limited. Inorder of importance, samples are collected to derive the followingparameters: 1) Cmax and 2) estimation of CL. Sampling for measurement ofSBC-102 serum levels on Day 0 (Dose 1) and Day 105 (Lose 16) arecollected. In all subjects, samples are collected pre-dose (within 30minutes of dosing); at 90(±5) minutes after the start of the infusion;and at 110(±5) minutes after the start of the infusion. All PK samples,at time points that coincide with a vital sign assessment, are to betaken before cuff inflation for BP assessment on the non-infusion arm.PK samples at other time points are taken at least 5 minutes after cuffdeflation.

Example 5 Dose Preparation and Infusion

SBC-102 is provided in single dose 10 mL glass vials as a clear liquid.The solution (total 10.5 mL including 5% overfill) has a concentrationof 2 mg·mL⁻¹. All SBC-102 vials were stored at a controlled temperatureof 2-8° C. Vials are frozen and protected from light during storage. Thesyringe containing SBC-102 diluted in 0.9% saline was preparedimmediately before infusion. When the syringe of SBC-102 had beenprepared in advance, the diluted solution was labeled and used within 4hours of preparations.

The patient's weight, as recorded prior to dosing on the morning of theinfusion and rounded to the nearest 0.1 kg, was used for calculatingSBC-102 volume for each infusion. The total infusion volumes used in thestudy are based on the dosing regimen shown in Table 2.

TABLE 2 Dose Infusion Volume 0.35 mg/kg 10 mL   1 mg/kg 10 mL   3 mg/kg20 mL

Dose preparation and administration should be performed using sterile,non-pyrogenic disposable materials including, but not restricted tosyringes, needles, transfer tubing and stopcocks.

The infusion rate on the flow-regulating device should be set toadminister the total volume over approximately 120 minutes as shown inTable 3.

TABLE 3 Infusion Rate per Infusion Rate per Infusion Rate per Dose Hourminute kilogram per hour 0.35 mg/kg  5 mL 0.083 mL 0.175 mg/kg/hr   1mg/kg  5 mL 0.083 mL  0.5 mg/kg/hr   3 mg/kg 10 mL 0.167 mL  1.5mg/kg/hr

Example 6 Adverse Events (AEs)

In subjects who experience AEs or infusion related reactions (IRR) withclinically significant cardiovascular, respiratory, or other effects,the infusion should be discontinued and the subject must be treated foran anaphylactic reaction according to institutional guidelines forsevere infusion reaction management in children less than 2 years ofage. This may include intravenous antihistamines, corticosteroids, andepinephrine, if necessary. For related biological products, the majorityof delayed IRRs occur more than 24 hours after the infusion. Symptomsinclude arthralgia, myalgia, influenza-like symptoms, headache,tiredness, and rash or urticaria. Delayed reactions can be treated withanalgesics or antihistamines as clinically indicated. IRRs areclassified as either acute (occurring within 24 hours of the start ofthe infusion) or delayed (occurring between 1 and 6 days after theinfusion). Medications and equipment for the treatment ofhypersensitivity reactions must be available for immediate use in caseof unexpected, severe hypersensitivity reactions. These suppliesinclude, but are not restricted to, oxygen, acetaminophen,antihistamines (e.g., diphenhydramine, parenteral and PO),corticosteroids, epinephrine and cardiopulmonary resuscitation devices.In similar biological products, most acute IRRs occur within 24 hours ofthe infusion (Cerezyme®, VPRIV®, Fabrazyme® prescribing information).Signs of a possible acute IRR can be categorized as: mild to moderateIRRs: hyperemia, flushing, fever and/or chills, nausea, pruritus,urticaria, gastro-intestinal symptoms (vomiting, diarrhea, abdominalcramping). Mild reactions are defined as self limiting, spontaneouslyresolving reactions after temporary cessation or a reduction in theinfusion rate. Moderate reactions are defined as reactions which do notresolve with simple measures, require extended observation and therapydiscontinuation. Severe IRR entails chest pain, dyspnea, wheezing,stridor, hypotension or hypertension, respiratory arrest, apnea,dyspnea, bradycardia or tachycardia. If any of the above signs andsymptoms are observed during the infusion and the subject remainshemodynamically stable, the infusion rate can be slowed (reduced to halfthe rate being given at the onset of the event, e.g. from 10 mL·hr⁻¹ to5 mL·hr⁻¹) and the infusion time extended. Once the event has resolved,the infusion should continue for a minimum of 30 minutes at the reducedrate before the rate is increased to 75% of the original rate on theinfusion schedule. If the subject continues to show signs ofhypersensitivity, an IM or slow IV dose of an antihistamine may beadministered according to institutional guidelines for infusion reactionmanagement in children less than 2 years of age.

Example 7

Administration of rhLAL to a Human Patient with Late Onset LALDeficiency

The primary objective of the study is to evaluate the safety andtolerability of SBC-102 in patients with liver dysfunction due to lateonset LAL Deficiency (vital signs, physical examination, clinicallaboratory tests, immunogenicity tests, adverse event assessment,concomitant therapies). The secondary objective is to characterize thepharmacokinetics of SBC-102 delivered by IV infusion after single andmultiple doses (pre and post infusion Day 0 and 21). Inclusion criteriafor late onset LAL deficiency subjects are as follows:

-   -   1. Patient understands the full nature and purpose of the study,        including possible risks and side effects, and is willing and        able to comply with all study procedures and provide informed        consent;    -   2. Male or female patients ≥18 and ≤65 years of age;    -   3. Documented decreased LAL activity relative to the normal        range of the lab performing the assay or documented result of        molecular genetic testing confirming diagnosis of LAL        Deficiency;    -   4. Evidence of liver involvement based on clinical presentation        (hepatomegaly) and/or laboratory test results (ALT or        AST≥1.5×ULN);    -   5. If on a statin or ezetimibe, the patient must be on a stable        dose for at least 4 weeks prior to screening;    -   6. All women must have negative serum pregnancy test at        screening and cannot be breast feeding; and    -   7. Female patients of childbearing potential must agree to use a        highly effective and approved contraceptive method(s) for the        duration of the study and continue to use for 30 days after last        dose.

Clinical assessments include physical examinations, urinalysis, clinicalchemistry analyses, CBC/hematology, acute phase reactants, coagulationstudies, 12-lead ECG, Anti-SBC-102 antibodies, and PK to derive Cmax,AUC_(inf), T_(1/2), Cl and V_(SS).

The patients are given 0.35 mg·kg⁻¹, 1 mg·kg⁻¹ or 3 mg·kg⁻¹ of LAL onceweekly via intravenous (IV) infusion over 2 hours. The first subject isdosed and monitored for tolerability for at least 24 hours beforeproceeding to dosing the other subjects in the cohort. Each subjectremains in-patient for 24 hours following their first infusion ofSBC-102. Subjects continue with an additional 3 doses of once weekly IVinfusions of the SBC-102 dose provided that tolerability and safetyremain acceptable.

Pharmacokinetics

PK data are analyzed using all subjects entered into the study receivingat least one dose of study medication excluding any data points whichmay have been influenced by a major protocol deviation. PK analysis areperformed using a one compartment infusion model. The following PKparameters are derived and presented by cohort (Cmax, AUC_(inf),T_(1/2), Cl and V_(SS)). Single and multiple dose PK parameters arecompared using Visit 2 and Visit 6 data.

The proposed increment between doses in this study can be 3, 4, 5 or6-fold, which may allow assessment of initial safety, tolerability, andpharmacokinetics in humans across a 6-fold range of doses on a mg·kg⁻¹basis. In a relevant preclinical rat model, the pharmacodynamic effectsof 1 mg·kg⁻¹ once weekly, 3 mg·kg⁻¹ every other week, and 5 mg·kg⁻¹ onceweekly are comparable. Thus, although it is not anticipated that dosesgreater than 3 mg·kg¹ once weekly subjects are required, dose more than3 mg·kg¹, such as 4, 5, 6, 7, 8, 9 or 10 mg·kg⁻¹ can be considereddepending on the severity of the disease.

Study Design

Given the rarity of patients with this condition, the targeted numberfor this study is 9 evaluable subjects. Subjects are enrolled in threesequential cohorts of 3 subjects per cohort. Subjects assigned to cohort1 commence dosing first, followed by those assigned to cohort 2, thenthose in cohort 3.

TABLE 4 Late Onset LAL Deficiency Study Schedule: Visits, Assessments,and Intervals Pre- Post Active treatment Active Phase Phase Visit VisitVisit Visit Visit Visit Visit 1 Visit Visit 4 5 6 7 7.1 8 (Day- 2 3 (DayTC (Day TC (Day TC (Day (Day (Day 28 to- (Day (Day 7 ± Day 14 ± Day 21 ±Day 28 ± 35 ± 52 ± Assessments 7) 0) 1) 1) 8 1) 15 1) 22 1) 1) 1)Informed Consent X Inclusion/Exclusion Criteria X X DemographicInformation X Patient Health Outcomes X M edical History¹ X 12-lead ECGX X Physical Examination X² X X X² X Vital Signs³ X X³ X X³ X³ X³ X XUrinalysis X X^(P) X^(P) X X X X X Pregnancy Test⁴ X X^(P) X^(P) XCBC/Hematology X X^(P) X^(P) X^(P) X^(P) X^(P) X X Chemistry Panel XX^(P) X^(P) X^(P) X^(P) X^(P) X X Liver Panel X X^(P) X^(P) X^(P) X^(P)X^(P) X X X Lipid Panel X X^(P) X Acute Phase Reactants X X^(P) X XCoagulation Tests X X Viral Hepatitis Screen X Autoimmune Hepatitis XScreen DNA Sample X Blood PBMC LAL activity X X^(P) X Anti SBC-102 Ab(ADA) X X^(P) X X Exploratory Biomarker X X^(P) X X X Sample PK Sample⁵X X SBC-102 Dosing X X X X Adverse Events X X X X X X X X X X X XConcominant Therapies X X X X X X X X X X X X TC = Telephone Call^(P)Pre-dose ¹Including alcohol history (AUDIT questionnaire) ²Includingheight and weight ³Pre-dose, every 15 minutes during infusion, every 15minutes for the 2 hours after the infusion and every 30 minutes forhours 2-4 after the infusion ⁴Serum at Visit 1 and Visit 8; urine atVisit 2 and Visit 6 ⁵Pre-dose, 10, 15, 20, 40, 60, 90 minutes during theinfusion, at the end of the infusion (approx. 120 minutes) and at 5, 10,20, 30, 40, 60 and 120 minutes after the infusion

Cohort 1

Three subjects receive IV infusions of 0.35 mg·kg⁻¹ of SBC-102. Thefirst subject is dosed and monitored for tolerability for at least 24hours before proceeding to dosing the other 2 subjects in the cohort.Each subject remains in-patient for 24 hours following their firstinfusion of SBC-102. Subjects continue with 3 additional IV infusions of0.35 mg·kg⁻¹ provided that tolerability and safety are acceptable.

Cohort 2

Three subjects receive IV infusions of 1 mg·kg⁻¹ of SBC-102. The firstsubject in Cohort 2 is dosed and monitored for tolerability for at least24 hours before proceeding to dosing the other 2 subjects in the cohort.Each subject remains in-patient for 24 hours following their firstinfusion of SBC-102. Subjects continue with 3 additional IV infusions of1 mg·kg⁻¹ provided that tolerability and safety are acceptable.

Cohort 3

Three subjects receive IV infusions of 3 mg·kg⁻¹ of SBC-102. The firstsubject in Cohort 3 is dosed and monitored for tolerability for at least24 hours before proceeding to dosing the other subjects in the cohort.Each subject remains in-patient for 24 hours following their firstinfusion of SBC-102. Subjects continue with 3 additional doses of onceweekly IV infusions of 3 mg·kg⁻¹, provided that tolerability and safetyare acceptable.

The Safety Committee (SC) may suspend dosing for an entire cohort or foran individual subject at any point due to poor tolerability or potentialsafety risks.

If the subject is discontinued from study treatment at a scheduled visitother than Visit 8 (End of Study) or at an unscheduled visit, thesubject should return no earlier than 7 days after the last dose ofSBC-102 for the End of Study assessments conducted at Visit 8.

SBC-102 is administered by IV infusion on Visits 2, 4, 5 and 6.Concomitant therapies are recorded throughout the study. Adverse eventsare recorded from the time of signing of the informed consent.

Each subject receives a total of four weekly doses of SBC-102 providedthat tolerability and safety remain acceptable.

Study Duration

The study involves 4-weeks of dosing with SBC-102 and a wash-out periodto support evaluation of safety and dosing scheduling for subsequentclinical trials. After completion of this study, subjects may beeligible to resume SBC-102 under a separate protocol to assess thelong-term safety and efficacy of SBC-102 in patients with LALDeficiency/CESD phenotype.

Physical Examination

A general physical examination is performed by a medically qualifiedperson. Systems (including, but not limited to, the cardiovascular,respiratory, gastrointestinal and neurological systems) should bespecified and recorded. Any abnormalities should be stated each time theexamination is performed. Diagnosis of new abnormalities should berecorded as adverse events, if applicable.

Additional physical examination assessments to be performed at theScreening Visit:

-   -   a) Liver size: A clinical assessment of liver size (palpable/non        palpable and centimeters below costal margin), regularity        (smooth/nodular) and sensitivity (tender/non tender) is made.    -   b) Lymphadenopathy: An assessment of the size, location, and        character of any palpable lymph nodes is made. Areas to be        examined include: cephalic (occipital, preauricular,        postauricular, submental, submandibular), cervical, clavicular,        axillary, and inguinal. Any enlarged nodes is characterized as        tender or non-tender.    -   c) Arterial disease: Right and left Posterior Tibialis and        Dorsalis Pedis pulses are assessed clinically and right and left        ankle brachial indexes (ABI) are recorded. ABI is defined as the        ratio of the systolic pressure at the dorsalis pedis or        posterial tibial artery divided by the right or left arm        brachial systolic pressure (whichever is higher).

Vital Signs

Vital signs, including pulse rate, respiratory rate, systolic anddiastolic blood pressure and temperature, are measured. Assessment ofpulse rate and blood pressure are taken after the subject has been in asemi-supine position for at least 5 minutes. On dosing days, vital signsare recorded pre-infusion, every 15 minutes (±5) during infusion and for2 hours after the infusion and then every 30 minutes (±10) between 2 and4 hours after the infusion is completed. Additional readings may betaken at the discretion of the Investigator in the event of an infusionrelated reaction (IRR). 12-lead electrocardiogram (ECGs) with formalrecordings are taken after the subject has been supine for at least 5minutes.

Laboratory Assessments

Samples for laboratory tests are collected at the time points indicatedin the Schedule of Assessments. The following analyses (with theexception of ESR, coagulation studies and anti-SBC-102 antibodies) areperformed.

-   -   CBC/Hematology: White blood cell count, red blood cell count,        hemoglobin, hematocrit, mean corpuscular volume (MCV), mean        corpuscular hemoglobin (MCH), mean corpuscular hemoglobin        concentration (MCHC), platelet count, neutrophil, lymphocytes,        monocytes, eosinophils, basophils    -   Chemistry Panel: Glucose, urea nitrogen, creatinine, sodium,        potassium, chloride, calcium, magnesium, inorganic phosphorus,        total protein, lactate dehydrogenase, uric acid    -   Liver Function Test: AST/SGOT, ALT/SGPT, alkaline phosphatase,        GGTP, albumin, bilirubin (direct, total)    -   Lipid Panel: Total cholesterol, triglyceride, HDL, LDL    -   Coagulation Studies: Prothrombin time (PT) international        normalized ratio (INR), activated partial thromboplastin time        (aPTT)    -   Urinalysis: Glucose, ketones, blood, pH, protein, nitrite, and        leukocytes (microscopic examination will only be done if blood,        protein, nitrite and/or leukocytes are abnormal)    -   Viral Hepatitis Screen: HBsAg and HCV serology (at screening or        if clinically indicated during trial)    -   Autoimmune Hepatitis Screen: anti-smooth muscle antibody (ASMA),        anti-nuclear antibodies (ANA), anti-LKM1 antibody, anti-SLA        antibody    -   Anti-drug Antibody: Anti-SBC-102 antibody    -   Acute Phase Reactants: High sensitivity C-reactive protein        (CRP), erythrocyte sedimentation rate (ESR) and serum ferritin    -   Pregnancy Test: All women have, at a minimum, monthly pregnancy        tests. These are performed using serum at Visit 1 and Visit 8        and urine at Visit 2 and Visit 6.

Pharmacokinetic (PK) assessments: PK samples are taken from the armopposite the infusion cannula. Intensive sampling for measurement ofSBC-102 serum levels on Day 0 (Dose 1, Visit 2) and Day 21 (Dose 4,Visit 6) is collected: immediately pre-dose (within 30 minutes ofdosing); At 10(±1), 15(±1), 20(±1), 40(±2), 60(±2) and 90(±2) minutesduring the infusion and at the end of the infusion (approximately 120minutes); and at 5(±1), 10(±1), 20(±1), 30(±1), 40(±2), 60(±2) and120(±2) minutes after completion of the infusion.

Preparation of SBC-102

The subject's weight recorded on Visit 1 is used for calculating SBC-102volume for each infusion. SBC-102 drug product for IV infusion isprepared by dilution using the following steps:

-   -   1. Vials are removed from the refrigerator.    -   2. It is confirmed that the expiration date on the vial has not        passed.    -   3. The calculated total volume of SBC-102 required for dosing is        determined.

EXAMPLE

-   -   Subject Wt (in kg): 70 kg    -   Subject dose level: 3 mg·kg⁻¹    -   Drug concentration: 2.0 mg·mL⁻¹

1. Calculation of Subject Dose:

$\frac{{{Weight}\mspace{14mu} \left( {{in}\mspace{14mu} {kg}} \right) \times {Dose}\mspace{14mu} {Level}} = {{Total}\mspace{14mu} {Dose}}}{{70\mspace{14mu} {kg} \times 3\mspace{14mu} {{mg} \cdot {kg}^{- 1}}} = {210\mspace{14mu} {mg}}}$

2. Calculation of Injection Volume:

$\frac{{{Total}\mspace{14mu} {daily}\mspace{14mu} {{dose} \div \begin{matrix}{{Drug}\mspace{14mu} {concentration}} \\{{in}\mspace{14mu} {vial}}\end{matrix}}} = \begin{matrix}{{Total}\mspace{14mu} {Injection}} \\{Volume}\end{matrix}}{{210\mspace{14mu} {{mg} \div 2.0}\mspace{14mu} {mg}\; {mL}^{- 1}} = {105\mspace{14mu} {mL}}}$

-   -   4. The following 0.9% saline infusion bags are used based on the        dosing group assignment:

Cohort Dose (mg · kg⁻¹) Infusion Bag Volume (mL) 1 0.35 100 2 1 3 3 250

-   -   5. A volume equivalent to the volume of SBC-102 required for        dosing (as calculated in step 3 above) is removed from either a        100 mL or 250 mL infusion bag of 0.9% saline (i.e., using the        example above, 105 mL of saline is removed from a 250 mL        infusion bag).    -   6. The calculated total volume of SBC-102 to the 0.9% saline        infusion bag is drawn up and transferred (i.e., using the        example above, 105 mL of SBC-102 solution is drawn up and        transferred to the infusion bag).    -   7. Gentle inversion is used to mix the bag.        Administration of rhLAL    -   1. The IV infusion tubing is attached to the diluted bag of        SBC-102.    -   2. The tubing is primed, and all air is expelled.    -   3. The infusion rate on the flow-regulating device is set to        administer the total volume at the following rates over        approximately 100 minutes:

Dose Infusion Rate Infusion Cohort (mg · kg⁻¹) (per hour) Rate (perminute) 1 0.35 60 mL 1 mL 2 1 3 3 150 mL 2.5 mL

-   -   4. The IV infusion site, which varies by subject and can include        antecubital or wrist veins (or a central venous catheter) is        selected.    -   5. The IV tubing is attached to the angiocatheter. Saline is        injected into the IV line to assess patency and to verify that        the saline flushes easily.    -   6. The IV line is secured with tape.    -   7. SBC-102 infusion is begun using a flow-regulating device.    -   8. Infusion is monitored regularly.    -   9. When the bag is empty, 25 mLs of 0.9% saline is immediately        injected into the infusion bag using the injection port.    -   10. The line is flushed at the same infusion rate (60 mL per        hour [1 mL per minute] for the 0.35 mg·kg⁻¹ and 1 mg·kg⁻¹ dose        and 150 mL per hour [2.5 mL per minute] for the 3 mg·kg⁻¹ dose)        until completion of the infusion. The end of the infusion is        defined when the infusion and flush has completed and is        documented.

Infusion Reactions

An infusion-related reaction (IRR) is defined as anyimmunologically-mediated adverse event that is at least possibly relatedto infusion. IRRs are classified as either acute (occurring within 24hours of the start of the infusion) or delayed (occurring between 1 and14 days after the infusion).

Medications and equipment for the treatment of hypersensitivityreactions must be available for immediate use in case of unexpectedsevere hypersensitivity reactions. They include, but are not restrictedto, oxygen, acetaminophen, antihistamines (e.g. diphenhydramine,parenteral and PO), corticosteroids, epinephrine (adrenaline) andcardiopulmonary resuscitation devices.

Signs of a possible acute IRR can be hyperemia, flushing, fever and/orchills, nausea, pruritus, urticaria, gastro-intestinal symptoms(vomiting, diarrhea, abdominal cramping), cardiopulmonary reactions,including chest pain, dyspnea, wheezing, stridor, hypotension orhypertension. If any of the above signs and symptoms is observed duringthe infusion and the subject remains hemodynamically stable: theinfusion rate must be slowed or stopped. If the subject continues toshow signs of hypersensitivity, an IM or slow IV dose of anantihistamine should be administered. In subjects who experience severeinfusion reactions with clinically significant cardiovascular orrespiratory effects, the infusion is discontinued. In such ananaphylactic reaction, subject can be treated with intravenousantihistamines, corticosteroids and epinephrine.

Example 8 Administration of Recombinant LAL in a Rat Model

The effects of repeat-dosing with recombinant human LAL on weight,tissue triglycerides and cholesterol, hepatomegaly, splenomegaly,lymphadenopathy, intestinal weight, and other parameters were evaluatedin LAL Deficient Donryu rats described in Yoshida and Kuriyama (1990)Laboratory Animal Science, vol 40, p 486-489 (see also Kuriyama et al(1990) Journal of Lipid Research, vol 31, p 1605-1611; Nakagawa et al,(1995) Journal of Lipid Research, vol 36, p 2212-2218), the disclosureof which is incorporated in its entirety herein by reference. At 4 weeksof age, Donryu rats which are homozygous for the LAL deletion (LAL−/−),were assigned into groups to either be dosed with recombinant human LALproduced in a transgenic chicken oviduct system or a saline placebo.Wild-type, age-matched, littermate rats were used as controls. TheLAL−/− rats were dosed once a week for four weeks (four doses total) oronce every two weeks for four weeks (two doses total) by tail-veininjection as a single dose or in two equal doses given 30 minutes apart.Doses of recombinant LAL were 1 mg/kg or 5 mg/kg. Dosing schedule isshown in Table 5. The rats were pretreated with diphenhydramine (5mg/kg) to counteract potential anaphylactic reactions, a procedure whichis based on previous experiences in animal models of enzyme replacementtherapy for the treatment of lysosomal storage disease (Shull et al.(1994) Proceedings of the National Academy of Science, vol 91, p. 12937;Bielicki et al. (1999) The Journal of Biological Chemistry, 274, p.36335; Vogler et al. (1999) Pediatric Research, 45, p. 838.), thedisclosure of which is incorporated in its entirty herein by referernce.

FIG. 9 shows the daily progress in weight gain of rats which wereadministered either 1 mg/kg of recombinant LAL per week or 5 mg/kg ofrecombinant LAL per week or 5 mg/kg of recombinant LAL per two weeks. Itcan be seen in the figure that there is little or no difference intherapeutic effect between the two dose sizes and frequencies.

TABLE 5 Weighing and Dosing Schedule of LAL Deficient Donryu rats Dayfrom Birth Assessments/Injections Performed Day 13 WEIGHED Day 14 Day 20Day 21 Pups Weaned Day 24 Day 25 Day 27 Day 28 First Injection foradministration once every week and once every two weeks Day 31 Day 32Day 34 Day 35 Second Injection for administration once every week Day 38Day 39 Day 41 Day 42 Third Injection for administration once every week;Second administration for once every two weeks Day 45 Day 48 Day 49Fourth injection for administration once every week Day 55 Day 56Necropsy

Example 9

Pathologic Examination of LAL−/− Rats Treated with Recombinant LAL

At the termination of the study described in Example 8, study animalswere humanely euthanized and necropsied to examine gross pathology,histopathology, and clinical chemistry. The gross necropsy includedexamination of the external surface of the body, all orifices, and thecranial, thoracic, and abdominal cavities and their contents. Mass ofinternal organs and tissues were determined for the rats and the organsand tissues were harvested and fixed in 10% neutral-buffered formalin.Following fixation, the tissues were processed and histological slidesof hematoxylin and eosin-stained sections were prepared and evaluated.

The gross pathological examination of treated animals analyzed showed asubstantial normalization in liver size and color as can be seen in thedissection shown in FIG. 10. Organ-to-body weight ratios were determinedand demonstrated a reduction in the relative organ size for liver,spleen, mesenteric tissue, duodenum, jejunum and ileum in successfullytreated animals which were dissected, as compared to the placebo treatedrats. Histopathology of liver tissue from recombinant LAL-treated ratsanalyzed shows essentially normal liver histology in marked contrast tothe substantial accumulation of foamy macrophages in the placebo-treatedanimals (FIG. 10).

Example 10 Internalization of Recombinant Human LAL in Macrophage andFibroblast Lysosomes

The ability of transgenic avian derived recombinant human LAL(“SBC-102”) to bind to cells and be internalized to the lysosomalcompartment, was examined in vitro using macrophage and fibroblastcells. When incubated with macrophage cells, fluorescently-labeledSBC-102 was found to localize to the lysosomes. This effect could beattenuated by using a mannose polysaccharide competitor, implicating theN-acetylglucosamine/mannose (GlcNAc/mannose) receptor as a mechanism ofrecognition and uptake by these cells. SBC-102 increased thecell-associated LAL activity in both LAL-deficient human fibroblasts andnormal murine fibroblasts after incubation in vitro, indicating thatexposure to SBC-102 can result in substantial replacement of deficientenzymatic activity.

Mannose-6-phosphate (M6P) is present in the oligosaccharide structuresof SBC-102 which have been shown to be involved in the delivery oflysosomal enzymes to a wide variety of cells types via the ubiquitousM6P receptor.

Recombinant LAL was purified from the egg white of transgenic hens.Oregon Green NHS was obtained from Invitrogen™ (#0-10241). The ratalveolar macrophage line, NR8383, and the mouse fibroblast line,NIH-3T3, were obtained from ATCC. LAL-deficient Wolman's fibroblastswere obtained from Coriell Institute for Medical Research andLysoTracker® Red was obtained from Invitrogen™.

Enzyme labeling: 4 mg of transgenic avian derived LAL in PBS was labeledwith Oregon Green, according to the manufacture's recommendations andreaction was subsequently dialyzed against PBS then concentrated.

Macrophage uptake: Fluorescently-labeled transgenic avian derived LAL (5μg/mL) and LysoTracker® Red were incubated with NR8383 cells for 2hours. Cells were examined by co-focal fluorescence microscopy using asequential scanning mode at 488 nm and then 514 nm.

Competitive inhibition with, mannan: Fluorescently-labeled SBC-102 (5ug/mL) and mannan were incubated with NR8383 cells for 2 hours. Cellswere trypsinized, and recombinant LAL uptake was measured byflorescence-activated cell sorting using median fluorescence intensityas the endpoint.

The ability of transgenic avian derived LAL to be taken up andsubsequently incorporated into the lysosomes of target cells wasexamined using the macrophage cell line, NR8383. Fluorescently-labeledtransgenic avian derived LAL and the lysosomal marker, “LysoTracker®Red” (Invitrogen™), were incubated with cells for 2 hours. Theco-localization of transgenic avian derived LAL and lysosomal marker inthe lysosomes of these cells was subsequently examined by confocalfluorescence microscopy using a sequential scanning mode (FIG. 11). Therecombinant LAL demonstrated localization to lysosomes, which isconsistent with similar in vitro studies using recombinant human (rhLAL)from a variety of sources.

The binding specificity of transgenic avian derived LAL to theGlcNAc/mannose receptor has been assessed by competitive binding assaysusing the macrophage cell line, NR8383 (FIG. 12). Fluorescently-labeled(Oregon Green) transgenic avian derived LAL at 5 μg/mL and variousconcentrations of the mannose-containing oligosaccharide, mannan, wereco-incubated with cells for 2 hours. The relative inhibition oftransgenic avian derived LAL uptake by mannan, as compared with nomannan control, was quantified by fluorescence-activated cell sortinganalysis using median fluorescence intensity as the endpoint. A mannosedose dependent inhibition in transgenic avian derived LAL binding/uptakewas observed, which is consistent with transgenic avian derived LAL:GlcNAcR interaction.

In addition, mannose-6-phosphate mediated uptake in fibroblast cells wasdemonstrated by competition experiments with mannose-6-phosphate.

Example 11 Increase of LAL Activity in Treated Cells

LAL catalyzes the hydrolysis of cholesterol esters and triglycerides tofree cholesterol, glycerol, and free fatty acids. Thus, LAL activity canbe measured, for example, by the cleavage of the fluorogenie substrate,4-methylumbelliferyl oleate (4MUO).

Fibroblasts

The ability of transgenic avian derived LAL exposure to increase LALactivity in cells has been examined using both normal and LAL-deficientcells in vitro. Fibroblasts were isolated from a Wolman's patient and anormal murine fibroblasts (NIH-3T3) were incubated in the presence oftransgenic avian derived LAL at concentrations of either 0, 0.16, or 0.5micrograms/mL for 5 hours. Cells were then washed to remove non-specificsignal, and cell lysates were assayed for LAL activity using4-methylumbelliferyl oleate (4-MUO) substrate. FIG. 13 demonstrates thatendogenous cell-associated LAL activity was lower in Wolman'sfibroblasts compared to NIH-3T3, and dose-dependent increases in LALactivity were observed in both cell types after incubation withtransgenic avian derived LAL (FIG. 13).

Leukocytes

Serum monocuclear leukocytes were obtained from LAL deficient patientspre- and post-administration. Blood samples were stored refrigeratedwithout loss of enzyme activity. Mononuclear leukocytes (lymphocytes)were isolated from blood using a preparation of Ficoll and sodiumdiatrizoate. 4-8 mL blood, previously diluted 1:1 with Hanks' balancedsalt solution, was layered gently over 3 mL Ficoll-Paque andcentrifuged. The mononuclear cell ring was aspirated and washed oncewith Hanks' solution, then at least twice by resuspending the pellet in1-2 mL water. Pellets were frozen at −20° C. before use. Prior to assay,pellets were thawed, resuspended in distilled water and sonicated onice. The preparation was then centrifuged at 20,000×g for 15 min at 4°C. The supernatant (containing 0.5-1.5 mg protein/mL) was kept on ice,prior to assay.

The substrate for the acid lipase assay was prepared by adding 1 ml 10mM 4MUO (4-methylumbelliferyl oleate) in hexane to 1 mL 16 mML-α-phosphatidylcholine in CHCI₃. The solvents were evaporated under N₂and 25 ml 2.4 mM taurodeoxycholic acid (sodium salt) in water wereadded. The mixture was sonicated on ice for 1-2 min at 30-40 W. Prior toassay, 1 vol. substrate stock was diluted with 7 vols. 200 mM sodiumacetate/acetic acid buffer (pH 4.0). Each 2 mL reaction cuvettecontained 100 nmol 4-methylumbelliferyl oleate, 160 nmolL-α-phosphatidylcholine and 600 nmol sodium taurodeoxycholate.

The reaction was started by adding 5-100 μL enzyme and was monitored at37° C. using a spectrophotofluorimeter. Cleavage of 4MUO was detected,for example, by excitation at about 360 nm and emission at about 460 nmof the released flurophore, 4-methylumbelliferone (4MU). The change influorescence with time was recorded.

Example 12 In Vivo Analysis of Recombinant Human LAL (SBC-102)

LAL-deficient Yoshida Rats (i.e., Homozygous) (see Kuriyama et al.(1990), Journal of Lipid Research, vol. 31, p 1605-1611; Nakagawa etal., (1995) Journal of Lipid Research, vol. 36, p 2212-2218; and Yoshidaand Kuriyama (1990) Laboratory Animal Science, vol. 40, p 486-489) weretreated with either SBC-102 (5 mg/kg, IV) or placebo, once/week for fourweeks beginning at four weeks of age. For each administration theSBC-102 was injected into the rat tail vein in two equal doses (2.5mg/kg) 30 minutes apart. Rats and aged-matched wild-type controls wereexamined one week after the final dose. Analyses were done intriplicate.

Gross pathologic examination of the SBC-102 treated animals demonstratednormalization in liver color in addition to reduction in organ size. TheSBC-102 treated rats showed essentially normal liver histology in markedcontrast to the substantial accumulation of foamy macrophages in thevehicle-treated animals. Serum alanine and aspartate transferase levels,which are elevated in LAL^(−/−) rats, were also reduced in SBC-102treated rats.

Mass of internal organs and tissue was determined for each rat and thedata is shown in FIG. 14. Organ size is represented as percent of bodyweight determined at 8 weeks of age, in LAL^(−/−) rats and LAL^(+/+)rats after weekly administration of vehicle or SBC-102 at 5 mg/kg for 4weeks.

Body weights of SBC-102- or vehicle-treated Yoshida rats were comparedwith wild type rats, as is shown in FIG. 15. SBC-102 (5 mg/kg) orvehicle was administered by IV injection either as a single dose or assplit doses (given within 4 hour period) to LAL^(−/−) rats. LAL^(+/+)rats were age-matched littermate controls.

Example 13 Triglyceride Analysis

Triglyceride analysis was performed on liver and spleen tissue from wildtype, homozygous placebo and homozygous SBC-102 treated animals. Thetriglyceride analyses were performed using standard methodologies (i.e.,MBL International's Triglyceride Quantification Kit Catalog #JM-K622-100) and were done in triplicate.

TABLE 6 Liver and Spleen Triglyceride levels in wild-type and LALdeficient rats Triglyceride (ug/mg wet tissue) SBC- Wild Type Placebo102 (n = 3) (n = 3) (n = 3) Liver 48 84 57 Spleen 3 22 4

Liver Substrate Levels

FIG. 16 shows liver cholesterol, cholesteryl ester and triglyceridelevels determined at 8 weeks of age, in WT and LAL deficient rats afterweekly administration of vehicle or SBC-102 at 5 mg·kg⁻¹ for 4 weeks.

Example 14 Rat Dose Response Study

Based on the studies performed above, the pharmacodynamic (PD) effectsof a range of doses and dose schedules (qw and qow) of LAL (“SBC-102”)were examined in LAL rats. In these studies, SBC-102 was administered byIV injections at dosages of 0.2, 1, 3 and 5 mg/kg, qow, or 0.35, 1.0 and5.0 mg/kg, qw, for 1 month, beginning at 4 weeks of age. Resultsdemonstrate improvements in body weight (BW) gain (FIG. 17),organomegaly (FIG. 18), and tissue substrate levels (FIG. 19). Serumtransaminase levels were also reduced as the SBC-102 dose increased,with levels reaching essentially wild-type levels at the higher doses.

Example 15 Pharmacokinetics of SBC-102

a. Sampling

PK samples were taken from adult patients suffering from late onset LALdeficiency. The patients were dosed with 0.35 mg/kg for two hours. Serumsamples on Day 0 (Dose 1, Visit 2) and Day 21 (Dose 4, Visit 6) werecollected immediately pre-dose (within 30 minutes of dosing); at 10(±1),15(±1), 20(±1), 40(±2), 60(±2) and 90(±2) minutes during the infusion(DI) and at the end of the infusion (EOI) (approximately 120 minutesfrom the beginning of the infusion); and at 5(1), 10(±1), 20(±1),30(±1), 40(±2), 60(±2) and 120(±2) minutes after completion of theinfusion (AI).

b. Serum Enzymatic Assay

4-MUO (4 mM) kept in −20° C. freezer was thawed in a 4° C. refrigeratorin the dark and placed in a 25° C. incubator for 1.5 hours in the darkprior to use. Standard was prepared by diluting SBC-102 drug product to1.56 ng/mL. A blank assay buffer was included. All samples were dilutedto 50 ng/mL for the first dilution. Standards and samples were platedimmediately after making dilutions. After standards and samples wereprepared, 62.5 uL of Assay Buffer (0.2 mol/L sodium acetate trihydrate,pH 5.5) was added to each well. 12.5 uL of standards and samples wereadded each well, in duplicate. 4-MUO (4 mM) was diluted to 1.6× with 4%Triton X-100 and added 25 uL per well. The multi-well plate was tapped afew times to mix, sealed tightly, and placed in a 37° C. incubator for30 minutes. After incubation, 50 uL of stop solution (0.77M Tris pH 8.0)was added to each well to make a final volume of 150 uL/well. The platewas placed on microplate leader and levels of fluorescence were measuredfrom the bottom of the plate at excitation of 360 nm and emission 460nm.

As shown in Tables 7-11, serum C_(max) of the recombinant LALadministered to adult patients suffering from late onset LAL deficiencyranged from approximately 270 ng/mL to 720 ng/mL. Half-life (t_(1/2))ranged from 7.6 minutes to 16.7 minutes, and the mean t_(1/2) wasapproximately 13 minutes (standard deviation, 3.812).

TABLE 7 Patient ID (Dose: 0.35 Concentration Nominal mg/kg) Visit #(ng/mL) Time 02-001 2 5.63 Pre- infusion 02-001 2 241.88 10 min DI02-001 2 369.44 15 min DI 02-001 2 369.93 20 min DI 02-001 2 359.64 40min DI 02-001 2 294.64 60 min DI 02-001 2 71.85 90 min DI 02-001 2 71.20EOI 02-001 2 37.95 5 min AI 02-001 2 24.91 10 min AI 02-001 2 14.16 20min AI 02-001 2 9.76 30 min AI 02-001 2 9.02 40 min AI 02-001 2 7.20 60min AI 02-001 2 7.51 120 min AI C_(max) = 369.93 ng/mL; t_(1/2) = 16.8min; LLOQ = 4.68 ng/ml

TABLE 8 Patient ID (Dose: 0.35 Concentration Nominal mg/kg) Visit #(ng/mL) Time 03-001 2 8.23 Pre 03-001 2 199.80 10 min DI 03-001 2 215.1015 min DI 03-001 2 228.12 20 min DI 03-001 2 237.25 40 min DI 03-001 2210.73 60 min DI 03-001 2 262.41 90 min DI 03-001 2 102.39 EOI 03-001 252.20 5 min AI 03-001 2 33.75 10 min AI 03-001 2 17.60 20 min AI 03-0012 12.17 30 min AI 03-001 2 10.82 40 min AI 03-001 2 9.39 60 min AI03-001 2 8.72 120 min AI C_(max) = 262 ng/mL; t_(1/2) = 15.3 min; LLOQ =4.68 ng/ml

TABLE 9 Patient ID (Dose: 0.35 Concentration Nominal mg/kg) Visit #(ng/mL) Time 03-002 2 <4.68 Pre- infusion 03-002 2 480.55 10 min DI03-002 2 531.16 15 min DI 03-002 2 613.85 20 min DI 03-002 2 717.75 40min DI 03-002 2 84.46 60 min DI 03-002 2 54.34 90 min DI 03-002 2 171.41EOI 03-002 2 87.95 5 min AI 03-002 2 49.70 10 min AI 03-002 2 16.47 20min AI 03-002 2 11.01 30 min AI 03-002 2 9.76 40 min AI 03-002 2 6.28 60min AI 03-002 2 5.19 120 min AI C_(max) = 718 ng/mL; t_(1/2) = 10.8 min;LLOQ = 4.68 ng/ml

TABLE 10 Patient ID (Dose: 0.35 Concentration Nominal mg/kg) Visit #(ng/mL) Time 02-001 6 5.12 Pre- infusion 02-001 6 249.91 10 min DI02-001 6 294.37 15 min DI 02-001 6 313.75 20 min DI 02-001 6 330.04 40min DI 02-001 6 245.48 60 min DI 02-001 6 262.78 90 min DI 02-001 681.09 EOI 02-001 6 32.10 5 min AI 02-001 6 20.39 10 min AI 02-001 610.74 20 min AI 02-001 6 8.08 30 min AI 02-001 6 6.38 40 min AI 02-001 65.82 60 min AI 02-001 6 <4.68 120 min AI C_(max) = 330 ng/mL; t_(1/2) =15.3 min; LLOQ = 4.68 ng/ml

TABLE 11 Patient ID (Dose: 0.35 Concentration Nominal mg/kg) Visit #(ng/mL) Time 03-001 6 6.63 Pre- infusion 03-001 6 317.45 10 min DI03-001 6 333.46 15 min DI 03-001 6 310.83 20 min DI 03-001 6 378.68 40min DI 03-001 6 234.49 60 min DI 03-001 6 246.07 90 min DI 03-001 6206.06 EOI 03-001 6 253.80 5 min AI 03-001 6 70.81 10 min AI 03-001 624.61 20 min AI 03-001 6 12.32 30 min AI 03-001 6 9.03 40 min AI 03-0016 7.18 60 min AI 03-001 6 5.56 120 min AI C_(max) = 379 ng/mL; t_(1/2) =7.7 min; LLOQ = 4.68 ng/ml

Example 16 Immunogenicity Analysis: Measurement of Anti-SBC-102

Each unknown, positive and negative sample was diluted 1:20 in 5% drymilk in 1×PBS and incubated at 4° C. for 12-18 hours on a rotator (500rpm). Prior to assay, the samples were centrifuged at 2000×g for 20minutes and the supernatant was removed to a new 1.5 ml tube.

SBC-102 was diluted in 1×PBS buffer to a concentration of 0.5 ug/mL, and100 uL was placed to each well of a 96-well ELISA plate. The plate wascovered with adhesive cover and incubated at room temperature for 8hours or overnight at 4° C. After incubation, wells were washed threetimes with 1× wash buffer. 200 uL of 5% BSA-IgG free was added to eachwell and the plate was sealed and incubated at 4° C. for 12-18 hours orroom temperature for 2 hours. After incubation, the wells were washedthree times with 1× wash buffer. 100 uL of each control sample, unknownsample, and negative sample was added to wells in triplicate. The platewas incubated at room temperature for 1.5 hours on microplate shaker(500 rpm). After incubation, the wells were washed three times with 1×wash buffer. 100 uL of biotinylated SBC-102 diluted in dilution bufferto a concentration of 100 ng/mL was added to each well, and the platewas incubated at room temperature for 1.5 hours on a microplate shaker(500 rpm). After incubation, the wells were washed with 1× wash buffer.100 uL of streptavidin-HRP conjugate diluted to 1:4000 in dilutionbuffer was added to each well. The plate was incubated at roomtemperature for 1.5 hour on microplate shaker (500 rpm). Afterincubation, the wells were washed four times with 1× wash buffer. 100 uLof TMB substrate was added to each well, and the plate was incubated for15 minutes in the dark. 50 uL of stop solution (0.5N H₂SO₄) was added toeach well to stop the reaction. OD at 450 nm was measured.

As tabulated in Table 12, the patients who received weekly dose of 0.35mg/kg of SBC-102 for 4 weeks did not exhibit elevated levels ofanti-SBC-102 antibody, suggesting that the enzyme replacement therapy bySBC-102 infusion does not elicit any significant immunogenicity in humanpatients. These patients did not exhibit any adverse events orinfusion-related reaction (IRR).

TABLE 12 SBC-102 Concentration Sample Mean OD Std. Dev. (ng/ml) Neg.Ctrol. 0.056 N/A 0 Pos. Ctrl. 1 0.076 0.005 15.6 Pos. Ctrl. 2 0.0900.003 31.2 Pos. Ctrl. 3 0.132 0.008 62.5 Pos. Ctrl. 4 0.201 0.009 125Pos. Ctrl. 5 0.349 0.019 250 Pos. Ctrl. 6 0.635 0.012 500 Pos. Ctrl. 70.958 0.101 1000 Patient ID Mean OD Std. Dev. 01-001 Visit1 0.053 0.00002-001 Visit1 0.051 0.000 02-001 Visit7 0.053 0.002 02-001 Visit8 0.0500.001 03-001 Visit1 0.051 0.001 03-001 Visit2 0.051 0.001 03-001 Visit70.050 0.000 03-002 Visit1 0.052 0.004 03-002 Visit2 0.056 0.006

Example 17 Treatment of Wolman Disease (WD) by Administration ofRecombinant LAL

At 7 weeks of age a female patient is admitted to the hospital becauseof difficulty in weight gain and poor progress since birth. At theinitial physical examination the patient weighs 3.6 kg (birth weight 3.7kg) and is thin, with loose skin folds. The abdomen is distended, withfirm hepatomegaly of 6 cm and firm splenomegaly of about 4 cm. Enlargedlymph nodes are noted in the groin and muscular activity is weak.

The initial hemoglobin level is 9.2 gm, platelets 506,000, and whiteblood cells 11,550. Urinalysis is normal, and bone marrow smears revealvacuolated lymphocytes and numerous foam cells. Serum chemicalmeasurements: total lipids 834 mg/100 ml, phospholipids 176 mg/100 ml,triglycerides 141 mg/100 ml, cholesterol 129 mg/100 ml, bilirubin 0.3mg/100 ml, alkaline phosphatase 9.0 BU %, SGOT 90 units, SGPT 50 units,cholinesterase 20 units, urea nitrogen 8.3 mg, fasting sugar 45 mg/100ml. CT scan of the abdomen shows hepatosplenomegaly and bilateralsymmetrically enlarged adrenal glands with calcification.

The patient is surgically implanted with a venous vascular access portfor dosing. After connecting the port to an ambulatory infusion machine,the patient is pretreated with 1 mg/kg of diphenhydramine 20 minutesprior to recombinant LAL infusion in order to counteract potentialanaphylactic infusion reactions. The patient is then administeredrecombinant LAL at 1 mg/kg over the course of 5 hours by intravenousinfusion. This therapy is repeated one time every 7 days indefinitely.

Within two weeks of administering the first dose of recombinant LAL, thepatient is evaluated for weight gain and size of key abdominal organs asdetermined by ultrasound. Laboratory results testing lysosomal acidlipase activity in the patient are also performed.

Example 18 Treatment of Cholesteryl Ester Storage Disease (CESD) byAdministration of Recombinant LAL

A 3-year-old boy with a pruritic abdominal rash is examined by hispediatrician. Upon abdominal examination, hepatomegaly is noted by thephysician and confirmed by ultrasound. At this point no diagnosis ismade and the patient is monitored periodically.

At age 8, he is admitted to the hospital with gastroenteritis. Lightmicroscopy of a liver biopsy shows increased intracytoplasmic glycogenand small lipid droplets in hepatocytes. Electron microscopy showsmembrane-bound lipid droplets with small electron dense granules. Aworking diagnosis of glycogen storage disease type III (DeBrancherdisease) is made, but skin fibroblast Debrancher activity is normal.

At age 10, hepatomegaly persists and a second liver biopsy is taken.light microscopy shows altered lobular architecture of the hepaticparenchyma with distended hepatocytes containing cytoplasmic granulesand vacuoles with mild periportal fibrosis. Fibroblast acid lipaseactivity is found to be 7% of normal, confirming the diagnosis of CESD.Plasma concentrations of total cholesterol (TC), triglycerides (TG),low-density lipoprotein cholesterol (LDL-C) are each above the 95thpercentile for age and sex at 7.51, 3.24 and 5.58 mmol/L, respectively,while plasma high-density lipoprotein cholesterol (HDL-C) is below the5th percentile at 0.47 mmol/L; he has combined hyperlipidemia(hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemiaand hyperbetalipoproteinemia).

The patient is surgically implanted with a venous vascular access portfor dosing. After connecting the port to an ambulatory infusion machine,the patient is pretreated with 5 mg/kg of diphenhydramine 20 minutesprior to recombinant LAL infusion in order to counteract potentialanaphylactic infusion reactions. The patient is then administeredrecombinant LAL at 5 mg/kg over the course of 5 hours by intravenousinfusion. This therapy is repeated one time every 14 days indefinitely.

Within two weeks of administering the first dose of recombinant LAL, thepatient is evaluated for weight gain and size of key abdominal organs asdetermined by ultrasound. Laboratory results testing lysosomal acidlipase activity in the patient are also performed.

Each example in the above specification is provided by way ofexplanation of the invention, not limitation of the invention. In fact,it will be apparent to those skilled in the art that variousmodifications, combinations, additions, deletions and variations can bemade in the present invention without departing from the scope or spiritof the invention. For instance, features illustrated or described aspart of one embodiment can be used in another embodiment to yield astill farther embodiment. It is intended that the present inventioncover such modifications, combinations, additions, deletions, andvariations.

All publications, patents, patent applications, internet sites, andaccession numbers/database sequences (including both polynucleotide andpolypeptide sequences) cited herein are hereby incorporated by referencein their entirety for all purposes to the same extent as if eachindividual publication, patent, patent application, internet site, oraccession number/database sequence were specifically and individuallyindicated to be so incorporated by reference.

1. A method of treating a human patient with a lysosomal acid lipase(LAL) deficiency comprising administering recombinant human LAL to thepatient, wherein the administration is sufficient to improve liverfunction.
 2. The method of claim 1, wherein the administration issufficient to normalize liver tests.
 3. The method of claim 1, whereinthe administration minimizes hepatomegaly.
 4. The method of claim 1,wherein the administration is sufficient to decrease liver size.
 5. Themethod of claim 1, wherein the administration is sufficient to decreaseserum levels of liver transaminases.
 6. The method of claim 1, whereinthe administration is sufficient to reduce lipid levels.
 7. The methodof claim 1, wherein the administration is sufficient to reducetriglyceride levels.
 8. The method of claim 1, wherein theadministration is sufficient to reduce cholesteryl esters.
 9. A methodof increasing LAL activity in a human patient with a LAL deficiencycomprising administering recombinant human LAL to the patient, whereinthe administration results in increased LAL activity in the patient. 10.The method of claim 9, wherein the administration is sufficient toincrease LAL activity in the patient by at least about 35 pmol/mg/min.11-65. (canceled)
 66. An isolated recombinant human lysosomal acidlipase (rhLAL) that contains N-linked glycans attached to Asn³⁶, Asn¹⁰¹,Asn¹⁶¹, Asn²⁷³ and Asn³²¹, as set forth in SEQ ID NO:1, wherein theN-linked glycans comprise bi-, tri- and tetra-antennary structures withN-acetylglucosamine (GlcNAc), mannose and/or manose-6-phosphate (M6P),and wherein the rhLAL comprises M6P-containing glycans at Asn¹⁰¹, Asn¹⁶¹and Asn²⁷³.
 67. The isolated rhLAL of claim 66, wherein the rhLAL doesnot contain sialic acid.
 68. The isolated rhLAL of claim 66, wherein therhLAL has a molecular weight of about 55 kD.
 69. The isolated rhLAL ofclaim 66, wherein the rhLAL has a specific activity of at least about100 U/mg.
 70. The isolated rhLAL of claim 66, wherein the rhLAL does notcomprise O-linked glycans.
 71. The isolated rhLAL of claim 66, whereinAsn⁷² of the rhLAL is not glycosylated.
 72. The isolated rhLAL of claim66, wherein the rhLAL has serum half-life (t_(1/2)) that is less than 40minutes.